<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">F1000Res</journal-id>
<journal-id journal-id-type="iso-abbrev">F1000Res</journal-id>
<journal-id journal-id-type="pmc">F1000Research</journal-id>
<journal-title-group>
<journal-title>F1000Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-1402</issn>
<publisher>
<publisher-name>F1000 Research Limited</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31807283</article-id>
<article-id pub-id-type="pmc">6871362</article-id>
<article-id pub-id-type="doi">10.12688/f1000research.18949.1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Distinct roles of
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> variants in neurological conditions</article-title>
<fn-group content-type="pub-status">
<fn>
<p>[version 1; peer review: 2 approved]</p>
</fn>
</fn-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Myers</surname>
<given-names>Scott J</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data Curation</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1154-4842</contrib-id>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Hongjie</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data Curation</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Jing-Qiong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Francis Chee Kuan</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5272-9990</contrib-id>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Traynelis</surname>
<given-names>Stephen F</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Low</surname>
<given-names>Chian-Ming</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1154-4842</contrib-id>
<xref ref-type="corresp" rid="c1">a</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<aff id="a1">
<label>1</label>Center for Functional Evaluation of Rare Variants (CFERV), Emory University, Atlanta, GA, USA</aff>
<aff id="a2">
<label>2</label>Department of Pharmacology and Chemical Biology, Emory University, Atlanta, GA, USA</aff>
<aff id="a3">
<label>3</label>Department of Neurology, Vanderbilt Brain Institute, Vanderbilt Kennedy Center of Human Development, Vanderbilt University, Nashville, TN, USA</aff>
<aff id="a4">
<label>4</label>Department of Anaesthesia, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore</aff>
<aff id="a5">
<label>5</label>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore</aff>
</contrib-group>
<author-notes>
<corresp id="c1">
<label>a</label>
<email xlink:href="mailto:phclowcm@nus.edu.sg">phclowcm@nus.edu.sg</email>
</corresp>
<fn fn-type="COI-statement">
<p>
<bold>Competing interests: </bold>SFT is PI on a research grant from Allergan and Janssen and Emory University School of Medicine, is a member of the SAB for Sage Therapeutics, is co-founder of NeurOp Inc, and receives royalties for software. SFT and SJM are co-inventors on Emory-owned Intellectual Property that includes allosteric modulators of NMDAR function.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>8</volume>
<elocation-id>F1000 Faculty Rev-1940</elocation-id>
<history>
<date date-type="accepted">
<day>8</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2019 Myers SJ et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="f1000research-8-20772.pdf"></self-uri>
<abstract>
<p>Rapid advances in sequencing technology have led to an explosive increase in the number of genetic variants identified in patients with neurological disease and have also enabled the assembly of a robust database of variants in healthy individuals. A surprising number of variants in the
<italic>GRIN</italic> genes that encode
<italic>N</italic>-methyl-D-aspartate (NMDA) glutamatergic receptor subunits have been found in patients with various neuropsychiatric disorders, including autism spectrum disorders, epilepsy, intellectual disability, attention-deficit/hyperactivity disorder, and schizophrenia. This review compares and contrasts the available information describing the clinical and functional consequences of genetic variations in
<italic>GRIN2A</italic> and
<italic>GRIN2B.</italic> Comparison of clinical phenotypes shows that
<italic>GRIN2A</italic> variants are commonly associated with an epileptic phenotype but that
<italic>GRIN2B</italic> variants are commonly found in patients with neurodevelopmental disorders. These observations emphasize the distinct roles that the gene products serve in circuit function and suggest that functional analysis of
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> variation may provide insight into the molecular mechanisms, which will allow more accurate subclassification of clinical phenotypes. Furthermore, characterization of the pharmacological properties of variant receptors could provide the first opportunity for translational therapeutic strategies for these
<italic>GRIN</italic>-related neurological and psychiatric disorders.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>NMDA receptors</kwd>
<kwd>GRIN2A</kwd>
<kwd>GRIN2B</kwd>
<kwd>GluN2A</kwd>
<kwd>GluN2B</kwd>
<kwd>mutations</kwd>
<kwd>neurological disorder</kwd>
<kwd>psychiatric disorders</kwd>
<kwd>autism</kwd>
<kwd>epilepsy</kwd>
<kwd>intellectual disability</kwd>
<kwd>ADHD</kwd>
<kwd>schizophrenia</kwd>
<kwd>precision medicine</kwd>
</kwd-group>
<funding-group>
<award-group id="fund-1" xlink:href="http://dx.doi.org/10.13039/501100001352">
<funding-source>National University of Singapore</funding-source>
<award-id>R184000261101</award-id>
</award-group>
<award-group id="fund-2" xlink:href="http://dx.doi.org/10.13039/100009633">
<funding-source>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding-source>
<award-id>R01HD08237</award-id>
</award-group>
<award-group id="fund-3" xlink:href="http://dx.doi.org/10.13039/100000065">
<funding-source>National Institute of Neurological Disorders and Stroke</funding-source>
<award-id>R01NS036654</award-id>
<award-id>R24NS092989</award-id>
<award-id>R35NS111619</award-id>
</award-group>
<funding-statement>HY was supported by the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institutes of Health (NIH) under award number R01HD08237. SFT was supported by the National Institute of Neurological Disorders and Stroke (NINDS) of the NIH under award numbers NIH-NINDS R01NS036654 and R24NS092989 and R35NS111619. C-ML was supported by National University of Singapore grant R184000261101. </funding-statement>
<funding-statement>
<italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic>
</funding-statement>
</funding-group>
</article-meta>
<notes>
<sec sec-type="editor-note">
<title>Editorial Note on the Review Process</title>
<p>
<ext-link ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p>
<p>The referees who approved this article are: </p>
<list list-content="reviewer-list" list-type="simple">
<list-item>
<p>
<named-content content-type="reviewer-name">Wenjun Gao</named-content>, Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA, USA
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
<list-item>
<p>
<named-content content-type="reviewer-name">David Lynch</named-content>, Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
</list>
</sec>
</notes>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Ionotropic glutamate receptors are ligand-gated ion channels that mediate excitatory synaptic transmission throughout the central nervous system. These receptors can be classified into at least three distinct families, and nomenclature is based on the initial discovery of selective activating agonists AMPA, kainate, and
<italic>N</italic>-methyl-
<sc>d</sc>-aspartate (NMDA) for their corresponding receptors, which arise from
<italic>GRIA</italic>,
<italic>GRIK</italic>, and
<italic>GRIN</italic> genes, respectively. The
<italic>GRIN</italic> gene family encodes three classes of NMDA receptor (NMDAR) subunits: the glycine-binding GluN1 (product of
<italic>GRIN1</italic>), glutamate-binding GluN2 (
<italic>GRIN2A</italic>,
<italic>GRIN2B</italic>,
<italic>GRIN2C</italic>, and
<italic>GRIN2D</italic>), and the enigmatic glycine-binding GluN3 (
<italic>GRIN3A</italic> and
<italic>GRIN3B</italic>), the role of which remains poorly understood
<sup><xref ref-type="bibr" rid="ref-1">1</xref>,
<xref ref-type="bibr" rid="ref-2">2</xref></sup>. Most NMDARs are tetrameric assemblies of two GluN1 and two GluN2 subunits. In terms of the evolutionary history of the NMDAR, it appears that four GluN2 paralogs (GluN2A–D) were produced by two rounds of gene duplication in a common vertebrate ancestor; the rounds diverged during early vertebrate evolution principally at their carboxyl-terminal domain (CTD)
<sup><xref ref-type="bibr" rid="ref-3">3</xref></sup>. The first round of duplication gave rise to two GluN2 genes (the ancestors of GluN2A/B and GluN2C/D), and the second round gave rise to the four extant paralogs
<sup><xref ref-type="bibr" rid="ref-4">4</xref></sup>. Having a common ancestry, GluN2A and GluN2B molecular structure and function should be similar, except for the divergent CTDs. However, there are strong differences between these two subunits on almost every level, including in how clinically relevant missense variants impact the receptor and patient. In this review, we will focus on the molecular and functional basis as to why GluN2A and GluN2B show strikingly different effects when missense mutations arise (for example,
<italic>de novo</italic> in key gating motifs and different neurological disorders).</p>
<sec>
<title>Glutamate receptor structure and function</title>
<p>All NMDAR subunits contain four semi-autonomous domains: an amino-terminal domain (ATD), agonist-binding domain (ABD), transmembrane domain (TMD), and CTD (
<xref ref-type="fig" rid="f1">Figure 1</xref>). The bilobed ABD of GluN2 binds
<sc>l</sc>-glutamate within a cleft between two rigid lobes, S1 and S2, which form a clamshell-like structure that undergoes pronounced conformation changes upon ligand binding. The S1 lobe of the ABD, which resides distal to the ion channel, forms an interface between the ABD of adjacent subunits, allowing them to act as dimers
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>. For NMDARs, one GluN1 and one GluN2 ABD form a dimer, two of which exist within each tetrameric receptor
<sup><xref ref-type="bibr" rid="ref-6">6</xref></sup>. The S2 lobe that is proximal to the channel contains primarily the polypeptide chain that connects the two transmembrane helices (M1 and M3) through flexible linkers and a two-turn helix (the pre-M1 helix) that lies parallel to the plane of the membrane. The S2 lobe undergoes considerable movement as the agonist binds to “close the clamshell” within the ABD of each subunit, which is the initial conformational change of several that ultimately lead to opening of the ion channel pore
<sup><xref ref-type="bibr" rid="ref-7">7</xref></sup>. This combination of agonist binding and clamshell closure provides the energy to drive channel opening in all ionotropic glutamate receptors
<sup><xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-8">8</xref>–
<xref ref-type="bibr" rid="ref-11">11</xref></sup>.</p>
<fig fig-type="figure" id="f1" orientation="portrait" position="anchor">
<label>Figure 1. </label>
<caption>
<title>Domains of
<italic>N</italic>-methyl-
<sc>d</sc>-aspartate (NMDA) receptors.</title>
<p>The crystal structure for GluN1/GluN2B receptors is shown in the left panel
<sup><xref ref-type="bibr" rid="ref-13">13</xref></sup> depicting the amino-terminal domain (ATD), the agonist-binding domain (ABD), and the transmembrane domain (TMD). Not shown is the intracellular carboxyl-terminal domain (CTD). The right panel displays a schematic of a
<italic>GRIN</italic> subunit, and the subdomains and the clamshell features of the ATD and ABD are indicated.</p>
</caption>
<graphic xlink:href="f1000research-8-20772-g0000"></graphic>
</fig>
<p>Most information on NMDAR location and function exists for diheteromeric receptors that are a tetrameric assembly of two GluN1 subunits and two identical GluN2 subunits
<sup><xref ref-type="bibr" rid="ref-1">1</xref>,
<xref ref-type="bibr" rid="ref-2">2</xref></sup>. NMDARs are maximally activated when glycine binds to the ABD of GluN1 and
<sc>l</sc>-glutamate binds to the ABD of GluN2
<sup><xref ref-type="bibr" rid="ref-1">1</xref></sup>. Three transmembrane helices (M1, M3, and M4) form the pore and are directly coupled to the ABD in all glutamate receptor subunits, and the pore is lined by a re-entrant loop (referred to as M2)
<sup><xref ref-type="bibr" rid="ref-12">12</xref>,
<xref ref-type="bibr" rid="ref-13">13</xref></sup> that controls ion permeation and block
<sup><xref ref-type="bibr" rid="ref-14">14</xref></sup>. Not surprisingly, single amino acid variants in these transmembrane helices, in the linkers that couple transmembrane helices to the ABD, and in the pore-lining re-entrant M2 loop can affect gating, ion permeation, and block
<sup><xref ref-type="bibr" rid="ref-15">15</xref>–
<xref ref-type="bibr" rid="ref-21">21</xref></sup>. Part of the activation gate—the structure that occludes the flux of ions in the closed state—involves the M3 segment, including a highly conserved motif (SYTANLAAF)
<sup><xref ref-type="bibr" rid="ref-10">10</xref></sup>. The process of opening and closing is highly dependent on these nine residues, residues in the pre-M1 region and a region preceding the fourth TMD
<sup><xref ref-type="bibr" rid="ref-1">1</xref>,
<xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-22">22</xref>–
<xref ref-type="bibr" rid="ref-24">24</xref></sup>.</p>
<p>The NMDAR is permeable to Ca
<sup>2+</sup> in addition to Na
<sup>+</sup> and K
<sup>+
<xref ref-type="bibr" rid="ref-14">14</xref>,
<xref ref-type="bibr" rid="ref-22">22</xref>,
<xref ref-type="bibr" rid="ref-25">25</xref>–
<xref ref-type="bibr" rid="ref-27">27</xref></sup>, and the intraneuronal Ca
<sup>2+</sup> entry subsequent to NMDAR activation can engage intracellular signaling systems that lead to changes in gene expression
<sup><xref ref-type="bibr" rid="ref-28">28</xref></sup>, changes in post-translational modifications
<sup><xref ref-type="bibr" rid="ref-29">29</xref></sup>, and ultimately changes in synaptic strength
<sup><xref ref-type="bibr" rid="ref-30">30</xref></sup>. Once the pore opens, extracellular Mg
<sup>2+</sup> can join the traffic of ions moving through the channel to reach a deep binding site in the pore, the occupancy of which establishes channel block in a voltage-dependent manner (reviewed in
<xref ref-type="bibr" rid="ref-14">14</xref>). This endows the receptor with the ability to detect neuronal activity (in the form of depolarization) and simultaneous synaptic activity (in the form of release of glutamate). This coincidence detector is a central feature enabling NMDARs to participate in some, but not all, forms of synaptic plasticity
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup>. Some NMDARs can undergo desensitization during persistent activation
<sup><xref ref-type="bibr" rid="ref-32">32</xref></sup>, and the time course of desensitization for NMDARs is much slower than that for AMPA receptors
<sup><xref ref-type="bibr" rid="ref-1">1</xref></sup>. Both speed and extent of desensitization are subunit-dependent
<sup><xref ref-type="bibr" rid="ref-33">33</xref>,
<xref ref-type="bibr" rid="ref-34">34</xref></sup>, providing further separation of temporal signaling properties that depend on the frequency of synaptic input
<sup><xref ref-type="bibr" rid="ref-35">35</xref></sup>.</p>
<p>There are profound differences in the properties of NMDARs that contain GluN2A compared with GluN2B. For example, the open probability with GluN2A is higher than with GluN2B
<sup><xref ref-type="bibr" rid="ref-35">35</xref>,
<xref ref-type="bibr" rid="ref-36">36</xref></sup>. In addition, glutamate and glycine are both less potent at GluN2A compared with GluN2B
<sup><xref ref-type="bibr" rid="ref-37">37</xref></sup> and thus GluN2A-containing NMDARs show a faster deactivation time course following removal of glutamate than GluN2B-containing NMDARs
<sup><xref ref-type="bibr" rid="ref-38">38</xref></sup>. The deactivation time course following glutamate removal sets the duration of the synaptic current
<sup><xref ref-type="bibr" rid="ref-39">39</xref></sup> and thus GluN2A NMDARs will produce a faster synaptic current in comparison with GluN2B. GluN2A-containing receptors also desensitize more rapidly than GluN2B-containing receptors, which show a much slower desensitization time course
<sup><xref ref-type="bibr" rid="ref-35">35</xref></sup>. These two receptors show different sensitivity to extracellular negative allosteric modulators such as Zn
<sup>2+
<xref ref-type="bibr" rid="ref-40">40</xref>,
<xref ref-type="bibr" rid="ref-41">41</xref></sup>, and the Zn
<sup>2+</sup> binding site in the ATD shows much higher potency for GluN2A than GluN2B
<sup><xref ref-type="bibr" rid="ref-42">42</xref></sup>. These functional properties, as well as the intracellular CTD that controls receptor targeting to different regions of the plasma membrane, will enable a variety of distinct functions for GluN2A- and GluN2B-containing NMDARs in neurons. There is strong evidence for perisynaptic NMDARs which could play a range of different roles
<sup><xref ref-type="bibr" rid="ref-43">43</xref>,
<xref ref-type="bibr" rid="ref-44">44</xref></sup>. Some evidence suggests that GluN2A preferentially distributes to the postsynaptic density, compared with GluN2B, which also distributes throughout the dendrite at extrasynaptic sites
<sup><xref ref-type="bibr" rid="ref-45">45</xref></sup>. This distinct localization has also been suggested to influence the participation of these two receptor subunits in different forms of synaptic plasticity
<sup><xref ref-type="bibr" rid="ref-46">46</xref>–
<xref ref-type="bibr" rid="ref-48">48</xref></sup>. Moreover, there are distinct roles of NMDARs of different subunit composition in neuroprotective signaling and cell death signaling that reflect both their localization and ability to pass current and Ca
<sup>2+
<xref ref-type="bibr" rid="ref-49">49</xref>–
<xref ref-type="bibr" rid="ref-52">52</xref></sup>. However, the subcellular distributions of GluN2A and GluN2B are not absolute, and both subunits can be found both synaptically and extrasynaptically.</p>
</sec>
<sec>
<title>Developmental expression profile of GluN2A and GluN2B</title>
<p>The temporal expression profile of different NMDAR subunits is precisely controlled to coincide with critical periods in the development of different brain structures
<sup><xref ref-type="bibr" rid="ref-53">53</xref>–
<xref ref-type="bibr" rid="ref-58">58</xref></sup>. Indeed,
<italic>GRIN2</italic> gene expression in the brain changes throughout the postnatal developmental stages
<sup><xref ref-type="bibr" rid="ref-59">59</xref></sup>. The GluN2B subunit is highly expressed in the prenatal stages and its expression drops at the postnatal stages, becoming focally expressed in the forebrain. However, GluN2A is expressed at apparently low levels in the prenatal stages and increases upon birth
<sup><xref ref-type="bibr" rid="ref-53">53</xref>,
<xref ref-type="bibr" rid="ref-60">60</xref></sup>. In rodents,
<italic>GRIN2A</italic> mRNA appears detectable by
<italic>in situ</italic> hybridization studies around postnatal day 6. There is a progressive developmental change from predominantly GluN1/GluN2B receptors to GluN1/GluN2A receptors in many brain regions
<sup><xref ref-type="bibr" rid="ref-58">58</xref>,
<xref ref-type="bibr" rid="ref-61">61</xref>–
<xref ref-type="bibr" rid="ref-63">63</xref></sup>, including thalamic and cortical neurons during the early postnatal development
<sup><xref ref-type="bibr" rid="ref-64">64</xref></sup>. The decrease in GluN2B-containing NMDARs at synapses is corroborated with the detection of shorter excitatory postsynaptic currents and a decrease in sensitivity to a specific GluN1/GluN2B receptor antagonist, ifenprodil
<sup><xref ref-type="bibr" rid="ref-65">65</xref>,
<xref ref-type="bibr" rid="ref-66">66</xref></sup>. The prenatal expression of
<italic>GRIN2B</italic> in NMDAR subunit has been taken as evidence for an important role in brain development, circuit formation, and possibly cell migration and differentiation
<sup><xref ref-type="bibr" rid="ref-67">67</xref></sup>. In early postnatal development and late embryogenesis, GluN2B expression dominates during rapid cortical synaptogenesis
<sup><xref ref-type="bibr" rid="ref-68">68</xref></sup>. Kutsuwada
<italic>et al</italic>. observed neonate lethality of global
<italic>GRIN2B</italic> knockout mice
<sup><xref ref-type="bibr" rid="ref-69">69</xref></sup>, whereas Tang
<italic>et al</italic>. reported that overexpression of
<italic>GRIN2B</italic> in the forebrain of mice enhanced spatial memory performance and long-term hippocampal potentiation
<sup><xref ref-type="bibr" rid="ref-70">70</xref></sup>.
<bold></bold>
</p>
<p>It is not surprising that the many recent reports on human variants in
<italic>GRIN</italic> genes show different clinical phenotypes (discussed below) given that the modular structure of the receptor can compartmentalize the different actions of variants in different domains, thereby impacting different functional modalities. In addition, the distinct roles of GluN2A and GluN2B in synaptic signaling and circuit function enabled by their different developmental expression profile
<sup><xref ref-type="bibr" rid="ref-58">58</xref>,
<xref ref-type="bibr" rid="ref-61">61</xref>–
<xref ref-type="bibr" rid="ref-63">63</xref></sup>, the compartmentalization
<sup><xref ref-type="bibr" rid="ref-62">62</xref></sup>, and the functional attributes mean that variants in these two genes could have very different effects and different age-dependent phenotypes. For example, more pronounced effects might be observed for
<italic>GRIN2B</italic> variants in terms of neurodevelopment, and effects of the mutations might present early in postnatal stages and manifest as neurodevelopmental disorders, developmental delays (DDs), and intellectual disability (ID)
<sup><xref ref-type="bibr" rid="ref-71">71</xref></sup>. However, the effect of
<italic>GRIN2A</italic> will start to show in the later postnatal stage as the expression of
<italic>GRIN2A</italic> starts to increase and thus the influence of GluN2A-containing NMDARs becomes important. Most of the GluN2A variants were identified in patients with epileptic seizures and epileptic encephalopathies
<sup><xref ref-type="bibr" rid="ref-72">72</xref></sup>. In most cases when variants reduce Mg
<sup>2+</sup> inhibition and otherwise show enhanced NMDAR function, the patients show epileptic encephalopathy (EE), which may reflect not just DD from persistent and intractable seizures but perhaps excitotoxic neuronal cell death
<sup><xref ref-type="bibr" rid="ref-73">73</xref></sup>. Interestingly, variants in GluN1 will impact all NMDARs and thus would be expected to have even further distinct effects compared with
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic>
<sup><xref ref-type="bibr" rid="ref-74">74</xref></sup>. However, in this review, we restrict our summary of recent studies to rare
<italic>de novo</italic> variants discovered in the
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> genes. We highlight an emerging understanding of the functional and clinical consequences of these variants in the context of receptor expression, localization, and the unique roles that GluN2A and GluN2B subunits play. We speculate that viewing the phenotypic differences for patients with
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> through the lenses of these different properties will provide greater insight into disease mechanism and this information will create the possibility of instituting mechanism-based novel therapeutic treatments.</p>
</sec>
<sec>
<title>The increase in genetic information identifies a large number of disease-associated variants</title>
<p>The number of rare variants associated with neurological disease is expanding rapidly. Since the identification of the first disease-causing variants in NMDARs in 2010
<sup><xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-76">76</xref></sup>, over 500 variants in all
<italic>GRIN</italic> genes coding for NMDARs—found in all four semi-autonomous domains, (the ATD, the ABD, the TMD, and the CTD)—have been reported in ClinVar or from patient cohorts in the literature. These include 249 variants in the
<italic>GRIN2A</italic> and 204 variants in the
<italic>GRIN2B</italic> (ClinVar). The increasing use of next-generation whole exome sequencing in clinical practice promises to identify even more rare
<italic>de novo</italic> variants in
<italic>GRIN</italic> genes linked to neurological disorders as diagnostic whole exome sequencing efforts expand and become common practice outside academic medical centers
<sup><xref ref-type="bibr" rid="ref-71">71</xref>,
<xref ref-type="bibr" rid="ref-77">77</xref>,
<xref ref-type="bibr" rid="ref-78">78</xref></sup>. The rapid identification of numerous rare genetic variants should be followed by functional analysis of these variants, which, though more time-intensive, is an essential step in establishing their role in neurological disease. In addition, functional evaluation provides mechanistic insight toward disease etiology and potential treatment options. Fortunately, the NMDARs encoded by these genes can be easily expressed in heterologous systems and their function, though complex, is reasonably well understood
<sup><xref ref-type="bibr" rid="ref-1">1</xref>,
<xref ref-type="bibr" rid="ref-2">2</xref>,
<xref ref-type="bibr" rid="ref-6">6</xref></sup>. Multiple groups are expanding efforts to fill the gap between genetic identification of rare variants and elucidation of their functional consequences
<sup><xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-23">23</xref>,
<xref ref-type="bibr" rid="ref-73">73</xref>,
<xref ref-type="bibr" rid="ref-74">74</xref>,
<xref ref-type="bibr" rid="ref-79">79</xref>–
<xref ref-type="bibr" rid="ref-98">98</xref></sup>. With continued effort, all disease-associated variants eventually should be identified and functional characterization of these variants will inform the subdivision of variants into a limited set of groups with more homogenous clinical and functional phenotypes. This will allow direct comparison of variants with similar effects between different subunits and help elucidate the roles that these subunits play during development. It will also transform diagnoses and treatment options since variant function eventually will be readily available for clinicians in real time. However, at the moment, there remains a significant lag in efforts to obtain this functional information compared with the amount of new sequencing being performed.</p>
</sec>
</sec>
<sec>
<title>Comparison of patient phenotype for
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> missense and nonsense variants</title>
<p>Among the variants identified in the
<italic>GRIN</italic> gene family, those in
<italic>GRIN2A</italic> (46%) and
<italic>GRIN2B</italic> (38%) account for the vast majority, followed by
<italic>GRIN1</italic> variants (14%; ClinVar)
<sup><xref ref-type="bibr" rid="ref-72">72</xref></sup>. It is important to note that all of these genes can co-assemble to form functional receptors, meaning that the
<italic>GRIN</italic> variants should be thought of as a larger set of variants since variants in all three genes can produce similar gain-of-function (GoF) or loss-of-function (LoF) effects on NMDARs. Moreover, every NMDAR contains GluN1 and thus these variants in particular will impact both GluN2B- and GluN2A-containing NMDARs. However, there will be differences in the overall effects for
<italic>GRIN2A</italic> versus
<italic>GRIN2B</italic> genes depending on their regional and developmental expression profile, in addition to the different roles that they can play in circuit function. Thus, it will be useful to stratify variants by gene and by GoF and LoF even though they impact an overlapping set of NMDAR complexes expressed in the brain. Given that the most common
<italic>GRIN</italic> variants are in
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic>, a comprehensive evaluation of these two subunits provides an opportunity to understand the structural, functional, and genetic bases for disorders that these patients have. Functional consequences of many
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> variants have been assessed in heterologous expression systems and so we will focus on the effects of rare variants in these two genes.</p>
<p>An assessment of the genetic variation in the healthy population together with an evaluation of
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> variants in patients with neurological disease provides information about the regional tolerance of different domains of the GluN2 subunit. This approach reveals insight into protein function and information about the regions of the receptor that cannot tolerate even modest changes in amino acid side chain properties
<sup><xref ref-type="bibr" rid="ref-81">81</xref></sup>. Such regions appear to have undergone purifying selection and this determination can aid in future
<italic>in silico</italic> predictions of the impact of missense variants. Evaluation of
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> revealed that the ABD, TMDs, and the linker regions between these domains were particularly intolerant to genetic variation and suggests that these domains are under greater selection pressure
<sup><xref ref-type="bibr" rid="ref-82">82</xref>,
<xref ref-type="bibr" rid="ref-83">83</xref></sup>. These two regions appear to harbor the most disease-associated variants within the
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> genes
<sup><xref ref-type="bibr" rid="ref-72">72</xref>,
<xref ref-type="bibr" rid="ref-82">82</xref>–
<xref ref-type="bibr" rid="ref-84">84</xref></sup>. Evaluation of phenotypic severity for a cohort of patients harboring
<italic>GRIN2A</italic> variants showed stratification in severity across variants with different functional effects and localizations
<sup><xref ref-type="bibr" rid="ref-85">85</xref></sup>. There are some subtle differences in regions that are insensitive to variation that reflects different functions of GluN2A and GluN2B subunits. There are examples where different patients (that is, different genetic backgrounds) harbor the same
<italic>de novo GRIN</italic> missense variant in their genome; in these cases, the patients display similar but non-identical clinical phenotypes
<sup><xref ref-type="bibr" rid="ref-21">21</xref>,
<xref ref-type="bibr" rid="ref-23">23</xref>,
<xref ref-type="bibr" rid="ref-84">84</xref>–
<xref ref-type="bibr" rid="ref-88">88</xref></sup>. As the databases of genetic variation within the standing population expand, there will be an ever-increasing precision with which we can define intolerant regions, and we expect that more specific examples of intolerant regions that differ between the two subunits will emerge. In this review, we also compiled a list of
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> variants with phenotypes published in the literature and not found in the gnomAD database (
<ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org">http://gnomad.broadinstitute.org</ext-link>;
<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" orientation="portrait" position="anchor">
<label>Table 1. </label>
<caption>
<title>Phenotypes reported across
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> subdomains.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="2" valign="middle">Phenotypes (top) or Variant Type (bottom)</th>
<th align="center" colspan="6" rowspan="1" valign="middle"># reported in
<italic>GRIN2A</italic> / # reported in
<italic>GRIN2B</italic>
</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" valign="bottom">ATD</th>
<th align="center" colspan="1" rowspan="1" valign="bottom">ABD</th>
<th align="center" colspan="1" rowspan="1" valign="bottom">ABD-TMD
<break></break>Linkers</th>
<th align="center" colspan="1" rowspan="1" valign="bottom">TMD</th>
<th align="center" colspan="1" rowspan="1" valign="bottom">CTD</th>
<th align="center" colspan="1" rowspan="1" valign="bottom">Other</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Epi</td>
<td align="center" colspan="1" rowspan="1" valign="top">25 / 3</td>
<td align="center" colspan="1" rowspan="1" valign="top">41 / 13</td>
<td align="center" colspan="1" rowspan="1" valign="top">5 / 4</td>
<td align="center" colspan="1" rowspan="1" valign="top">19 / 12</td>
<td align="center" colspan="1" rowspan="1" valign="top">9 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">26 / 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ID</td>
<td align="center" colspan="1" rowspan="1" valign="top">28 / 13</td>
<td align="center" colspan="1" rowspan="1" valign="top">32 / 35</td>
<td align="center" colspan="1" rowspan="1" valign="top">4 / 9</td>
<td align="center" colspan="1" rowspan="1" valign="top">19 / 23</td>
<td align="center" colspan="1" rowspan="1" valign="top">8 / 9</td>
<td align="center" colspan="1" rowspan="1" valign="top">22 / 15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ASD</td>
<td align="center" colspan="1" rowspan="1" valign="top">4 / 6</td>
<td align="center" colspan="1" rowspan="1" valign="top">5 / 13</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">4 / 3</td>
<td align="center" colspan="1" rowspan="1" valign="top">2 / 6</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Language delay/Verbal dyspraxia/Aphasia syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top">14 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">22 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">5 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">10 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">7 / 0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LKS</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ADHD/Rett-like syndrome/Behaviorial anomalies</td>
<td align="center" colspan="1" rowspan="1" valign="top">2 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 1</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IS</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CVI</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 3</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hypotonia/Dystonia</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">9 / 1</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">2 / 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LGS</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">MD</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">4 / 2</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">West syndrome</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dysmorphic features</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">2 / 1</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ/Bipolar disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 2</td>
<td align="center" colspan="1" rowspan="1" valign="top">2 / 0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Macrocephaly or Abnormality of nervous system</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="center" colspan="1" rowspan="1" valign="top">12 / 7</td>
<td align="center" colspan="1" rowspan="1" valign="top">31 / 29</td>
<td align="center" colspan="1" rowspan="1" valign="top">4 / 8</td>
<td align="center" colspan="1" rowspan="1" valign="top">20 / 23</td>
<td align="center" colspan="1" rowspan="1" valign="top">7 / 8</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nonsense variant</td>
<td align="center" colspan="1" rowspan="1" valign="top">8 / 4</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 2</td>
<td align="center" colspan="1" rowspan="1" valign="top">3 / 2</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Splice junction variant</td>
<td align="center" colspan="1" rowspan="1" valign="top">9 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">7 / 3</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">0 / 1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Frame-shift variant</td>
<td align="center" colspan="1" rowspan="1" valign="top">5 / 4</td>
<td align="center" colspan="1" rowspan="1" valign="top">9 / 1</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">4 / 0</td>
<td align="center" colspan="1" rowspan="1" valign="top">2 / 3</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Indel variant</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 0</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">1 / 1</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Other</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">31 / 17</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>The table compares genetic variants in
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> genes with phenotypes as reported in the literature and absent in the gnomAD database (
<ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/">http://gnomad.broadinstitute.org</ext-link>). ABD, agonist-binding domain; ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ATD, amino-terminal domain; CTD, carboxyl-terminal domain; CVI, cerebral visual impairment; Epi, epilepsy/seizures; ID, intellectual disability (including developmental delay); IS, infantile spasms; LGS, Lennox–Gastaut syndrome; LKS, Landau–Kleffner syndrome; MD, movement disorder; SCZ, schizophrenia; and TMD, transmembrane domains (M1-M4). Other, refers to chromosome deletions, insertions, duplications that affect
<italic>GRIN2A</italic> or
<italic>GRIN2B</italic> genes. References
<xref ref-type="bibr" rid="ref-21">21</xref>,
<xref ref-type="bibr" rid="ref-73">73</xref>,
<xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-76">76</xref>,
<xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-82">82</xref>–
<xref ref-type="bibr" rid="ref-86">86</xref>,
<xref ref-type="bibr" rid="ref-89">89</xref>–
<xref ref-type="bibr" rid="ref-92">92</xref>,
<xref ref-type="bibr" rid="ref-94">94</xref>,
<xref ref-type="bibr" rid="ref-96">96</xref>,
<xref ref-type="bibr" rid="ref-98">98</xref>–
<xref ref-type="bibr" rid="ref-101">101</xref>,
<xref ref-type="bibr" rid="ref-103">103</xref>–
<xref ref-type="bibr" rid="ref-153">153</xref>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec>
<title>GRIN2A predominantly is associated with epilepsy and intellectual disability</title>
<p>More than 240 missense and nonsense variants have been reported for
<italic>GRIN2A</italic>.
<italic>De novo</italic> variants in
<italic>GRIN2A</italic> can be found in phenotypically normal neonates with a structurally normal brain at birth
<sup><xref ref-type="bibr" rid="ref-85">85</xref>,
<xref ref-type="bibr" rid="ref-89">89</xref></sup>. Multiple patients appear to have had uncomplicated pregnancies and normal deliveries with excellent appearance, pulse, grimace, activity, respiration (APGAR) scores and no immediate complications. However, patients can begin to show neurological abnormalities at a young age (during the first year of life)
<sup><xref ref-type="bibr" rid="ref-89">89</xref></sup>, presumably as a result of increasing expression of
<italic>GRIN2A</italic> with development
<sup><xref ref-type="bibr" rid="ref-60">60</xref></sup>. This most often manifests as abnormal electroencephalography (EEG) and myoclonic jerks progressing to a seizure disorder. Several studies have suggested that benign focal epilepsy with centrotemporal spikes (BECTS) seems to be caused by both missense and nonsense
<italic>de novo</italic> mutations within the
<italic>GRIN2A</italic> gene: Three reports from 2013 showed that
<italic>GRIN2A</italic> gene variants are more likely to occur in epilepsy subtypes that are believed to be a more severe variant of BECTS such as atypical benign partial epilepsy of childhood, Landau–Kleffner syndrome, and continuous spike waves during slow wave sleep
<sup><xref ref-type="bibr" rid="ref-99">99</xref>–
<xref ref-type="bibr" rid="ref-101">101</xref></sup>. An intriguing aspect of these epilepsy patients who harbor
<italic>GRIN2A</italic> variants is that the variants can produce both GoF and LoF, as inferred by nonsense variants that produce protein truncation. Patients with a deletion that removes the
<italic>GRIN2A</italic> gene also show hyperexcitability
<sup><xref ref-type="bibr" rid="ref-76">76</xref></sup>. The mechanisms that ultimately promote hyperexcitability in patients lacking
<italic>GRIN2A</italic> are not yet known, but likely due to haploinsufficiency although it appears that they in some way enhance circuit excitability
<sup><xref ref-type="bibr" rid="ref-102">102</xref></sup>. Interestingly, there is no firm evidence to suggest that
<italic>GRIN2A</italic> variants contribute to the two most common epilepsy syndromes: idiopathic generalized epilepsy and temporal lobe epilepsy
<sup><xref ref-type="bibr" rid="ref-154">154</xref></sup>.
<italic>GRIN2A</italic> variants are linked to autism spectrum disorder (ASD) but to a lesser degree than seen with
<italic>GRIN2B</italic> variants (
<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p>
<italic>GRIN</italic> variants have been identified both by screening of a select set of genes assembled as a panel or by whole exome sequencing, which provides good coverage over much of the exome, although certain GC-rich regions of DNA (for example, the 5' region of
<italic>GRIN2D</italic>) are often under-represented. Nevertheless, these approaches have discovered a large number of
<italic>de novo</italic> variants in neurological patients. A functional analysis has been published in the peer-reviewed literature for a number of
<italic>GRIN2A</italic> variants
<sup><xref ref-type="bibr" rid="ref-73">73</xref>,
<xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-79">79</xref>,
<xref ref-type="bibr" rid="ref-83">83</xref>,
<xref ref-type="bibr" rid="ref-86">86</xref>,
<xref ref-type="bibr" rid="ref-90">90</xref>–
<xref ref-type="bibr" rid="ref-93">93</xref></sup>. In addition, there is a comprehensive functional summary on the websites as a resource (
<ext-link ext-link-type="uri" xlink:href="http://functionalvariants.emory.edu">http://functionalvariants.emory.edu</ext-link>). Below, a subset of these published variants is discussed to illustrate some important commonalities and distinctions.</p>
<p>The functional consequences of several variants reported in the gnomAD database, some of which showed functional changes, were evaluated. One clinical case report is for a missense variant (GluN2A-V452M) from a patient with early infantile EE/Ohtahara syndrome
<sup><xref ref-type="bibr" rid="ref-155">155</xref></sup>. Another example of a variant proposed to cause a disease phenotype is a heterozygous
<italic>GRIN2A</italic> variant that produces GluN2A-N447K in a male with Rolandic epilepsy. EEG monitoring showed remarkable interictal high voltage spikes and spike-and-slow waves in the bilateral central-temporal regions, predominantly on the right hemisphere. The GluN2A-N447K variant is located in the S1 segment of the extracellular ABD of GluN2A. Residue N447 is highly conserved across higher vertebrates yet the Asn447Lys variant is present multiple times in gnomAD. Whole cell patch clamp recording of GluN2A-N447K reveals a GoF effect and an increase in NMDAR current density by about 1.2-fold, an enhancement of glutamate potency by two fold, and reduced sensitivity to Mg
<sup>2+</sup> inhibition
<sup><xref ref-type="bibr" rid="ref-93">93</xref></sup>. Experimental substitution of Asn447 to alanine (uncharged) or glutamic acid (negatively charged) did not change NMDAR function, suggesting that the positive charge associated with lysine may have altered NMDAR function. The patient became seizure-free when treated with a combination of valproate and lamotrigine
<sup><xref ref-type="bibr" rid="ref-93">93</xref></sup>.</p>
<p>A child with epileptic encephalopathy (EE) and severe cognitive impairment possessed a GoF missense
<italic>GRIN2A</italic> variant that produced GluN2A-L812M. This position in the linker between the ABD and TMD regions is intolerant to change, as all amino acid substitutions (seven to date) at this position produced a GoF variant that showed increased agonist potency, increased open probability, and reduced sensitivity to endogenous negative modulators such as extracellular Mg
<sup>2+</sup> and protons
<sup><xref ref-type="bibr" rid="ref-73">73</xref></sup>. The variant NMDARs’ activities were enhanced by virtually every measure and would be expected to lead to profound overactivation, which could drive excitotoxic mechanisms. Memantine is able to inhibit the GluN2A-L812M-containing NMDARs, and treatment with memantine led to a persistent reduction of the child’s seizure burden
<sup><xref ref-type="bibr" rid="ref-89">89</xref></sup>.</p>
<p>A heterologous
<italic>de novo</italic> variant was found in a 3-year-old female with early-onset EE, abnormal EEG, and severe DD
<sup><xref ref-type="bibr" rid="ref-75">75</xref></sup>. The variant substituted an evolutionarily conserved asparagine for a lysine (GluN2A-N615K) in the membrane re-entrant loop, which lines the channel pore and creates a constriction that controls ion selectivity of the channel
<sup><xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-156">156</xref>,
<xref ref-type="bibr" rid="ref-157">157</xref></sup>. This variant alters the voltage-dependent channel block by Mg
<sup>2+</sup> and decreases in Ca
<sup>2+</sup> permeability. Co-expression of GluN2-N615K with GluN1 and wild-type GluN2A in the same receptor complex, called triheteromeric receptors (comprised of GluN1:GluN2A:GluN1:GluN2A-N615K subunits), produces an intermediate effect, indicating that the negative impact caused by the variant on channel properties cannot be fully negated by the presence of one normal subunit copy of GluN2A in the receptor complex
<sup><xref ref-type="bibr" rid="ref-21">21</xref>,
<xref ref-type="bibr" rid="ref-92">92</xref></sup>.</p>
</sec>
<sec>
<title>
<italic>GRIN2B</italic> is predominantly associated with developmental delay, intellectual disability, and autism spectrum disorder</title>
<p>Over 200 variants in
<italic>GRIN2B</italic> are found in patients from cohorts with any one of several neurodevelopmental disorders
<sup><xref ref-type="bibr" rid="ref-71">71</xref></sup> such as ID (including DD)
<sup><xref ref-type="bibr" rid="ref-14">14</xref>,
<xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-82">82</xref>–
<xref ref-type="bibr" rid="ref-84">84</xref>,
<xref ref-type="bibr" rid="ref-91">91</xref>,
<xref ref-type="bibr" rid="ref-94">94</xref>–
<xref ref-type="bibr" rid="ref-96">96</xref>,
<xref ref-type="bibr" rid="ref-98">98</xref>,
<xref ref-type="bibr" rid="ref-103">103</xref>–
<xref ref-type="bibr" rid="ref-108">108</xref>,
<xref ref-type="bibr" rid="ref-111">111</xref>,
<xref ref-type="bibr" rid="ref-112">112</xref>,
<xref ref-type="bibr" rid="ref-114">114</xref>,
<xref ref-type="bibr" rid="ref-120">120</xref>,
<xref ref-type="bibr" rid="ref-122">122</xref>,
<xref ref-type="bibr" rid="ref-123">123</xref>,
<xref ref-type="bibr" rid="ref-128">128</xref>,
<xref ref-type="bibr" rid="ref-130">130</xref>,
<xref ref-type="bibr" rid="ref-135">135</xref>,
<xref ref-type="bibr" rid="ref-139">139</xref>–
<xref ref-type="bibr" rid="ref-147">147</xref>,
<xref ref-type="bibr" rid="ref-149">149</xref>–
<xref ref-type="bibr" rid="ref-153">153</xref></sup>, ASD
<sup><xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-82">82</xref>,
<xref ref-type="bibr" rid="ref-84">84</xref>,
<xref ref-type="bibr" rid="ref-91">91</xref>,
<xref ref-type="bibr" rid="ref-98">98</xref>,
<xref ref-type="bibr" rid="ref-104">104</xref>,
<xref ref-type="bibr" rid="ref-105">105</xref>,
<xref ref-type="bibr" rid="ref-108">108</xref>,
<xref ref-type="bibr" rid="ref-111">111</xref>,
<xref ref-type="bibr" rid="ref-135">135</xref>,
<xref ref-type="bibr" rid="ref-140">140</xref>,
<xref ref-type="bibr" rid="ref-144">144</xref>,
<xref ref-type="bibr" rid="ref-148">148</xref>,
<xref ref-type="bibr" rid="ref-151">151</xref>–
<xref ref-type="bibr" rid="ref-153">153</xref></sup>, EE and seizure disorders
<sup><xref ref-type="bibr" rid="ref-21">21</xref>,
<xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-82">82</xref>,
<xref ref-type="bibr" rid="ref-84">84</xref>,
<xref ref-type="bibr" rid="ref-98">98</xref>,
<xref ref-type="bibr" rid="ref-103">103</xref>,
<xref ref-type="bibr" rid="ref-120">120</xref>,
<xref ref-type="bibr" rid="ref-130">130</xref>,
<xref ref-type="bibr" rid="ref-135">135</xref>,
<xref ref-type="bibr" rid="ref-138">138</xref>,
<xref ref-type="bibr" rid="ref-139">139</xref>,
<xref ref-type="bibr" rid="ref-141">141</xref>,
<xref ref-type="bibr" rid="ref-145">145</xref></sup>, schizophrenia
<sup><xref ref-type="bibr" rid="ref-71">71</xref>,
<xref ref-type="bibr" rid="ref-111">111</xref>,
<xref ref-type="bibr" rid="ref-114">114</xref>,
<xref ref-type="bibr" rid="ref-137">137</xref>,
<xref ref-type="bibr" rid="ref-148">148</xref></sup>, and, to a lesser extent, attention-deficit/hyperactivity disorder
<sup><xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-84">84</xref>,
<xref ref-type="bibr" rid="ref-106">106</xref></sup>, cerebral visual impairment
<sup><xref ref-type="bibr" rid="ref-158">158</xref>,
<xref ref-type="bibr" rid="ref-146">146</xref></sup>, and Alzheimer’s disease
<sup><xref ref-type="bibr" rid="ref-159">159</xref></sup> have been reported in the literature. For these various phenotypes, virtually all of the patients display mild to profound DD or ID or both. In addition to exhibiting these neurological phenotypes, some patients exhibit abnormalities in muscle tone that includes spasticity or hypotonia
<sup><xref ref-type="bibr" rid="ref-158">158</xref>,
<xref ref-type="bibr" rid="ref-151">151</xref></sup>.
<italic>GRIN2B</italic> has been linked as a potential gene in which variations could increase the risk of autism
<sup><xref ref-type="bibr" rid="ref-104">104</xref>,
<xref ref-type="bibr" rid="ref-105">105</xref>,
<xref ref-type="bibr" rid="ref-160">160</xref></sup>. A number of other characteristics, including microcephaly, movement disorders, Rett-like syndrome, language disorders have been observed in some patients
<sup><xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-96">96</xref>,
<xref ref-type="bibr" rid="ref-115">115</xref>,
<xref ref-type="bibr" rid="ref-142">142</xref>,
<xref ref-type="bibr" rid="ref-158">158</xref></sup>.</p>
<p>The
<italic>GRIN2B</italic> variants identified thus far occur throughout the entire NMDAR subunit protein. That is, missense and nonsense variants have been identified in the ATD, ABD, TMD, and CTD domains. Homozygous
<italic>Grin2b</italic>-deletion mice die at early postnatal stages because of impaired suckling response and show impaired hippocampal long-term depression, whereas heterozygous mice show reduced expression of GluN2B but survive
<sup><xref ref-type="bibr" rid="ref-69">69</xref></sup>. Thus,
<italic>GRIN2B</italic> is an essential gene for normal development.
<italic>GRIN2B de novo</italic> variants with neurological diseases have been reviewed
<sup><xref ref-type="bibr" rid="ref-71">71</xref>,
<xref ref-type="bibr" rid="ref-77">77</xref>,
<xref ref-type="bibr" rid="ref-161">161</xref></sup>, and functional data exist for many
<italic>GRIN2B</italic> variants in published scientific journals (see below) or online databases (
<ext-link ext-link-type="uri" xlink:href="http://functionalvariants.emory.edu">http://functionalvariants.emory.edu</ext-link>).</p>
<p>Large cohort studies for ID or ASD have identified that LoF variants in
<italic>GRIN2B</italic> segregate with a broad spectrum of these neurological phenotypes
<sup><xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-105">105</xref></sup>. One such LoF variant is the missense variant GluN2B-E413G
<sup><xref ref-type="bibr" rid="ref-106">106</xref></sup>, which produces DD and ID. Studies conducted on neural progenitor cells (NPCs) generated from induced pluripotent stem cells found that neurons with heterozygous GluN2B-E413G, which is in the glutamate-binding pocket, caused a 50-fold decrease in glutamate signaling and reduced the maturation states of the neurons. Verification of failure to phosphorylate serine 133 in cAMP response element-binding protein (CREB) by NMDAR stimulation further confirms that the E413G variant in GluN2B impaired NMDAR signaling in the NPCs
<sup><xref ref-type="bibr" rid="ref-94">94</xref></sup>. This study shows that GluN2B-containing NMDARs are critical for signal transduction in neural stem cells and deﬁcits in this process impair cellular differentiation. The E413G variant is in close proximity to the glutamate-binding site but is not in physical contact with the agonist glutamate. Modelling of the protein structure suggests that GluN2B-E413 can alter agonist dissociation by increasing the ability of water to compete with agonist binding, thereby accelerating glutamate unbinding and likely rendering the synaptic NMDAR response time course briefer than that for wild-type NMDARs
<sup><xref ref-type="bibr" rid="ref-82">82</xref>,
<xref ref-type="bibr" rid="ref-95">95</xref></sup>.</p>
<p>The
<italic>GRIN2B</italic> variant encoding GluN2B-C461F, which was identified in a patient with Lennox–Gastaut syndrome and autistic features, is a LoF NMDAR variant. Cys461 is located in S1 of the ABD, close to the orthosteric glutamate-binding site. When co-transfected with GluN1-4b, an early developmental isoform of
<italic>GRIN1</italic>, GluN1:GluN2B-C461F receptors reduced glutamate potency by 71-fold compared with wild-type controls
<sup><xref ref-type="bibr" rid="ref-80">80</xref></sup>. This is in keeping with decreased glutamatergic neurotransmission in animal models of ASD (for example, BTBR mice), in which the phenotype can be improved by a selective AMPAKINE (AMPA receptor–positive allosteric modulator). Lennox–Gastaut syndrome is a severe type of childhood epilepsy. Also, during early development, high expression of variant GluN2B subunits could compromise neurotransmitter-based signaling (for example, GABA release via presynaptic NMDARs), circuit operation between distinct cell types (interneurons/principal neurons), and the balance of excitation and inhibition
<sup><xref ref-type="bibr" rid="ref-80">80</xref></sup>. This is in line with the association of mutations in
<italic>GABRB3</italic> with Lennox–Gastaut syndrome and autism
<sup><xref ref-type="bibr" rid="ref-162">162</xref>–
<xref ref-type="bibr" rid="ref-164">164</xref></sup>. In addition, synaptic pruning and synapse refinement are GluN2-dependent events that occur generally at a time of a switch in subunit expression from GluN2B to GluN2A
<sup><xref ref-type="bibr" rid="ref-64">64</xref></sup> and thus could be influenced by altered GluN2B function. This could be one contributing factor that is an underlying substrate for developmental effects of
<italic>GRIN2B</italic> variants
<sup><xref ref-type="bibr" rid="ref-165">165</xref></sup>.</p>
<p>The GluN2B-P553L variant was identified in a patient with severe ID
<sup><xref ref-type="bibr" rid="ref-107">107</xref></sup>. This variant was found to minimally affect glutamate potency, but the rate of desensitization of GluN1–GluN2B-P553L was markedly increased and currents were small in HEK cells
<sup><xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-83">83</xref></sup>. Pro553 is located at the proximal end of the first TMD, within the pre-M1 linker that connects S1 to M1. Spatially, P553 is adjacent to the highly conserved nine-residue signal-transduction element (SYTANLAAF) in M3 of the same subunit, which is involved in coupling ligand binding to channel opening, and controls channel open probability
<sup><xref ref-type="bibr" rid="ref-6">6</xref></sup>. Thus, the variant Pro553Leu may form different interactions with Asn649 or Leu650 (or both) in the SYTANLAAF motif, which could interfere with gating.</p>
<p>GluN2B-N615I and GluN2B-V618G variants are both associated with West syndrome, which is a triad of infantile spasms, hypsarrhythmia, and ID
<sup><xref ref-type="bibr" rid="ref-103">103</xref></sup>. GluN2B-N615 and -V618 are located in the M2 re-entrant loop, which forms part of the ion channel. N615 is located just above the narrowest constriction in the pore, which is also influenced by analogous residues in the GluN1 subunit (for example, GluN1-N616). Val618 in GluN2B is located deep in the channel pore, within the M2-M3 linker and with the CH
<sub>3</sub> side chain that has been suggested to be rotated away from the channel pore. This side-chain will interact with residues in M2 and M3 membrane helices of GluN1
<sup><xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-98">98</xref></sup>. For GluN2B-N615I and GluN2B-V618G, voltage-dependent Mg
<sup>2+</sup> inhibition was lost, resulting in a GoF phenotype that will allow increased NMDAR current under normal resting conditions, which may underlie increased neuronal excitability in West syndrome. The onset of symptoms in the patient coincided with the high expression profile of GluN2B in late infancy (&lt;1 year old)
<sup><xref ref-type="bibr" rid="ref-62">62</xref>,
<xref ref-type="bibr" rid="ref-103">103</xref></sup>.</p>
</sec>
<sec>
<title>Variants at the same residue position in GluN2A and GluN2B resulted in different disease phenotypes</title>
<p>A variant in both
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> that occurs at the same homologous position of these GluN2 subunits in NMDAR has been identified. Functionally, both GluN2A-N615K and GluN2B-N615I and GluN2B-N615K variants that substitute an evolutionarily conserved asparagine in the membrane re-entrant loop resulted in a loss of Mg
<sup>2+</sup> block
<sup><xref ref-type="bibr" rid="ref-21">21</xref>,
<xref ref-type="bibr" rid="ref-75">75</xref>,
<xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-84">84</xref></sup>. However, the resulting neurological phenotypes were found to be different. A 3-year-old female with a GluN2A-N615K variant exhibits early-onset EE, an abnormal EEG, and a severe DD
<sup><xref ref-type="bibr" rid="ref-75">75</xref></sup>, whereas for a GluN2B-N615I variant, the patient had West syndrome, hypsarrhythmia, and ID due to neurodevelopment disorders
<sup><xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-84">84</xref></sup> and GluN2B-N615K patient had ID and DD
<sup><xref ref-type="bibr" rid="ref-84">84</xref></sup>. This further validates our hypothesis that rare variants in intolerant domains in
<italic>GRIN2A</italic> are more likely to cause an epileptic phenotype but that variants in
<italic>GRIN2B</italic> are more aligned with abnormal developmental phenotypes.</p>
<p>Other cases for which the genetic variants were found on different GluN2 subunits at a homologous amino acid are GluN2A-P552R and GluN2B-P553L. GluN2A-P552R was identified in a patient with delayed psycho-motor development, ID, inability to speak, and epilepsy since 9 months of age
<sup><xref ref-type="bibr" rid="ref-83">83</xref>,
<xref ref-type="bibr" rid="ref-107">107</xref></sup>. The GluN2A-P552R variant shows increased sensitivity to glutamate and glycine but with a slower activation and deactivation time course. The GluN2B-P553L variant presents in a patient with severe ID and DD
<sup><xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-83">83</xref>,
<xref ref-type="bibr" rid="ref-98">98</xref>,
<xref ref-type="bibr" rid="ref-107">107</xref></sup>. This variant was found to reduce glutamate potency by 1.7-fold but increase the rate of glutamate current desensitization
<sup><xref ref-type="bibr" rid="ref-80">80</xref>,
<xref ref-type="bibr" rid="ref-83">83</xref></sup>. Thus, whereas one variant should increase charge transfer for each synaptic current, the other should diminish it.</p>
<p>In most situations, the GluN2A or GluN2B variants exist as a single allele (that is, are heterozygous) in the patients and therefore patients also have one copy of the wild-type allele. Therefore, it would be important to understand the effects of rare variants in both diheteromeric and triheteromeric NMDARs. As the NMDARs exist as a heterotetramer with two obligatory GluN1 subunits, the possibility exists that a diheteromer (for example, GluN1/GluN2A/GluN1/GluN2A) or triheteromer (for example, GluN1/GluN2A/GluN1/GluN2B) harbors a single disease variant GluN2 subunit.</p>
<p>To understand the
<italic>GRIN2</italic> variant effects in the presence of wild-type allele, NMDAR subunits were engineered to co-express as GluN1/GluN2A/GluN1/GluN2A-P552R and GluN1/GluN2A-P552R/GluN1/GluN2A-P552R, analyzed for response time course to glutamate and glycine, and compared with wild-type control GluN1/GluN2A. Single channel recording from single copy variant–containing receptors did not alter mean channel open time or chord conductance as compared with the wild-type channel. For the NMDARs with two copies of GluN2A-P552R, there is a significant increase in mean open time and reduced channel conductance when compared with the wild-type or single copy mutant. These data suggest that the GluN2A-P552R variants can alter stability and conformation of the open pore or its access portals only when both GluN2A subunits contain the P552R variant
<sup><xref ref-type="bibr" rid="ref-83">83</xref></sup>.</p>
</sec>
</sec>
<sec>
<title>Precision medicine</title>
<p>As more precise diagnoses for individuals are achieved, the basis of disease etiology will be better defined. We anticipate that novel drug development and a more mechanism-based use of currently approved drugs can improve clinical outcomes. For pharmacological treatment, the knowledge of risk factors, disease subtype, or underlying genetic variation should allow a choice of therapies proven effective in individuals with similar characteristics. For rare variants that are thought to contribute to or cause a disease, unique treatments that alter the function of the target or its downstream effects could provide novel therapies. This collection of ideas together can be described as precision medicine, an idea that is enabled by recent advances in technology on multiple fronts. There are several opportunities for potential precision medicine among the
<italic>GRIN</italic> variants. For example, it seems reasonable that therapies already approved by the US Food and Drug Administration that inhibit NMDAR receptors might have utility against symptoms produced by GoF
<italic>GRIN</italic> variants provided that some of the ongoing neurological symptoms reflect expression of aberrant protein rather than errant processes during development or cell loss driven by excitotoxicity. Likewise, although there are no currently available NMDAR potentiators approved for clinical use, supplementation with the co-agonists glycine,
<sc>d</sc>-serine, or perhaps
<sc>d</sc>-cycloserine might provide a way to augment NMDAR function, although there remains no systematic evaluation of this possibility in animal models or patients
<sup><xref ref-type="bibr" rid="ref-96">96</xref></sup>.</p>
<p>Personalized medicine through pharmacological intervention on patients harboring
<italic>de novo GRIN2A</italic> and
<italic>GRIN2B</italic> variants has been attempted. However, caution must be exercised as the potential drugs available (for example, memantine) are non-selective blockers of NMDARs, meaning that one may induce a block at some sites that are not contributing to the pathology. Memantine binding was also affected by the presence of bound Mg
<sup>2+</sup> in the channel, which reduced memantine potency more for GluN2A and GluN2B than GluN2C or GluN2D
<sup><xref ref-type="bibr" rid="ref-166">166</xref></sup>. Kinetic and molecular docking results indicated overlapping sites for Mg
<sup>2+</sup> and memantine, with Mg
<sup>2+</sup> binding at the level of the asparagine residues, whereas memantine binds just above the channel pore
<sup><xref ref-type="bibr" rid="ref-167">167</xref></sup>. Among the NMDAR subtypes, memantine has been suggested to be more potent at GluN2C- and GluN2D-containing NMDARs, the latter of which are expressed in GABAergic interneurons
<sup><xref ref-type="bibr" rid="ref-53">53</xref>,
<xref ref-type="bibr" rid="ref-168">168</xref></sup>. Nevertheless, over-active receptors may be attenuated, and some degree of voltage-dependent block potentially restored, to compensate for a reduced Mg
<sup>2+</sup> block by a rare variant. However, again caution is emphasized as several distinct disease variants in the channel pore can also alter the effect of candidate therapies, and already there are examples among the
<italic>GRIN</italic> genes in which the variant renders a potential drug candidate less effective. For example, memantine was more potent at GluN1/GluN2B-N615I and less potent at GluN1/GluN2B-V618G, compared with wild-type receptors, which holds important implications for therapeutics. Interestingly, dextromethorphan showed increased potency for some variant receptors compared with wild-type receptors
<sup><xref ref-type="bibr" rid="ref-90">90</xref></sup>.</p>
<p>Of the various mutations studied in detail, two result in LoF (C461F and P553L) and two in GoF (N615I and V618G). On this basis, memantine cannot be considered an all-encompassing treatment for NMDAR mutations and will be therapeutically beneficial for only selected GoF channel variants unless compensatory NMDAR is large. Still, there are some examples in which NMDAR block by memantine showed some utility
<sup><xref ref-type="bibr" rid="ref-86">86</xref>,
<xref ref-type="bibr" rid="ref-89">89</xref>,
<xref ref-type="bibr" rid="ref-97">97</xref></sup>. The inhibition of NMDAR-mediated currents by memantine at negative membrane potentials was comparable between wild-type and N615I- or V618G-expressing neurons. This supports a role for this medication as a potential therapy to mimic a loss Mg
<sup>2+</sup> block at the potentials in neurons.</p>
</sec>
</body>
<back>
<ref-list>
<ref id="ref-1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Traynelis</surname><given-names>SF</given-names></name><name><surname>Wollmuth</surname><given-names>LP</given-names></name><name><surname>McBain</surname><given-names>CJ</given-names></name><etal></etal></person-group>:
<article-title>Glutamate receptor ion channels: structure, regulation, and function.</article-title>
<source/><italic toggle="yes">Pharmacol Rev.</italic>
<year>2010</year>;<volume>62</volume>(<issue>3</issue>):<fpage>405</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1124/pr.109.002451</pub-id>
<!--<pub-id pub-id-type="pmcid">2964903</pub-id>-->
<pub-id pub-id-type="pmid">20716669</pub-id></mixed-citation>
</ref>
<ref id="ref-2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>P</given-names></name><name><surname>Bellone</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group>:
<article-title>NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.</article-title>
<source/><italic toggle="yes">Nat Rev Neurosci.</italic>
<year>2013</year>;<volume>14</volume>(<issue>6</issue>):<fpage>383</fpage>–<lpage>400</lpage>.
<pub-id pub-id-type="doi">10.1038/nrn3504</pub-id>
<pub-id pub-id-type="pmid">23686171</pub-id></mixed-citation>
</ref>
<ref id="ref-3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>Emes</surname><given-names>RD</given-names></name><name><surname>Grant</surname><given-names>SG</given-names></name><etal></etal></person-group>:
<article-title>Evolution of NMDA receptor cytoplasmic interaction domains: implications for organisation of synaptic signalling complexes.</article-title>
<source/><italic toggle="yes">BMC Neurosci.</italic>
<year>2008</year>;<volume>9</volume>:<fpage>6</fpage>.
<pub-id pub-id-type="doi">10.1186/1471-2202-9-6</pub-id>
<!--<pub-id pub-id-type="pmcid">2257970</pub-id>-->
<pub-id pub-id-type="pmid">18197970</pub-id></mixed-citation>
</ref>
<ref id="ref-4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>Kopanitsa</surname><given-names>MV</given-names></name><name><surname>Indersmitten</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior.</article-title>
<source/><italic toggle="yes">Nat Neurosci.</italic>
<year>2013</year>;<volume>16</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1038/nn.3277</pub-id>
<!--<pub-id pub-id-type="pmcid">3979286</pub-id>-->
<pub-id pub-id-type="pmid">23201971</pub-id></mixed-citation>
</ref>
<ref id="ref-5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>JX</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name></person-group>:
<article-title>Dissecting diverse functions of NMDA receptors by structural biology.</article-title>
<source/><italic toggle="yes">Curr Opin Struct Biol.</italic>
<year>2019</year>;<volume>54</volume>:<fpage>34</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1016/j.sbi.2018.12.009</pub-id>
<!--<pub-id pub-id-type="pmcid">6592722</pub-id>-->
<pub-id pub-id-type="pmid">30703613</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734959284">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansen</surname><given-names>KB</given-names></name><name><surname>Yi</surname><given-names>F</given-names></name><name><surname>Perszyk</surname><given-names>RE</given-names></name><etal></etal></person-group>:
<article-title>Structure, function, and allosteric modulation of NMDA receptors.</article-title>
<source/><italic toggle="yes">J Gen Physiol.</italic>
<year>2018</year>;<volume>150</volume>(<issue>8</issue>):<fpage>1081</fpage>–<lpage>105</lpage>.
<pub-id pub-id-type="doi">10.1085/jgp.201812032</pub-id>
<!--<pub-id pub-id-type="pmcid">6080888</pub-id>-->
<pub-id pub-id-type="pmid">30037851</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/733689357">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karakas</surname><given-names>E</given-names></name><name><surname>Regan</surname><given-names>MC</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name></person-group>:
<article-title>Emerging structural insights into the function of ionotropic glutamate receptors.</article-title>
<source/><italic toggle="yes">Trends Biochem Sci.</italic>
<year>2015</year>;<volume>40</volume>(<issue>6</issue>):<fpage>328</fpage>–<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1016/j.tibs.2015.04.002</pub-id>
<!--<pub-id pub-id-type="pmcid">4464829</pub-id>-->
<pub-id pub-id-type="pmid">25941168</pub-id></mixed-citation>
</ref>
<ref id="ref-8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>GQ</given-names></name><etal></etal></person-group>:
<article-title>Structure of a glutamate-receptor ligand-binding core in complex with kainate.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>1998</year>;<volume>395</volume>(<issue>6705</issue>):<fpage>913</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/27692</pub-id>
<pub-id pub-id-type="pmid">9804426</pub-id></mixed-citation>
</ref>
<ref id="ref-9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>N</given-names></name><name><surname>Gouaux</surname><given-names>E</given-names></name></person-group>:
<article-title>Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>2000</year>;<volume>28</volume>(<issue>1</issue>):<fpage>165</fpage>–<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1016/s0896-6273(00)00094-5</pub-id>
<pub-id pub-id-type="pmid">11086992</pub-id></mixed-citation>
</ref>
<ref id="ref-10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sobolevsky</surname><given-names>AI</given-names></name><name><surname>Rosconi</surname><given-names>MP</given-names></name><name><surname>Gouaux</surname><given-names>E</given-names></name></person-group>:
<article-title>X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>2009</year>;<volume>462</volume>(<issue>7274</issue>):<fpage>745</fpage>–<lpage>56</lpage>.
<pub-id pub-id-type="doi">10.1038/nature08624</pub-id>
<!--<pub-id pub-id-type="pmcid">2861655</pub-id>-->
<pub-id pub-id-type="pmid">19946266</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1282072">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yelshanskaya</surname><given-names>MV</given-names></name><name><surname>Mesbahi-Vasey</surname><given-names>S</given-names></name><name><surname>Kurnikova</surname><given-names>MG</given-names></name><etal></etal></person-group>:
<article-title>Role of the Ion Channel Extracellular Collar in AMPA Receptor Gating.</article-title>
<source/><italic toggle="yes">Sci Rep.</italic>
<year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>1050</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-017-01146-z</pub-id>
<!--<pub-id pub-id-type="pmcid">5430913</pub-id>-->
<pub-id pub-id-type="pmid">28432359</pub-id></mixed-citation>
</ref>
<ref id="ref-12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Lü</surname><given-names>W</given-names></name><name><surname>Michel</surname><given-names>JC</given-names></name><etal></etal></person-group>:
<article-title>NMDA receptor structures reveal subunit arrangement and pore architecture.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>2014</year>;<volume>511</volume>(<issue>7508</issue>):<fpage>191</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nature13548</pub-id>
<!--<pub-id pub-id-type="pmcid">4263351</pub-id>-->
<pub-id pub-id-type="pmid">25008524</pub-id></mixed-citation>
</ref>
<ref id="ref-13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karakas</surname><given-names>E</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name></person-group>:
<article-title>Crystal structure of a heterotetrameric NMDA receptor ion channel.</article-title>
<source/><italic toggle="yes">Science.</italic>
<year>2014</year>;<volume>344</volume>(<issue>6187</issue>):<fpage>992</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1126/science.1251915</pub-id>
<!--<pub-id pub-id-type="pmcid">4113085</pub-id>-->
<pub-id pub-id-type="pmid">24876489</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718424884">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glasgow</surname><given-names>NG</given-names></name><name><surname>Siegler Retchless</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group>:
<article-title>Molecular bases of NMDA receptor subtype-dependent properties.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>2015</year>;<volume>593</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>95</lpage>.
<pub-id pub-id-type="doi">10.1113/jphysiol.2014.273763</pub-id>
<!--<pub-id pub-id-type="pmcid">4293056</pub-id>-->
<pub-id pub-id-type="pmid">25556790</pub-id></mixed-citation>
</ref>
<ref id="ref-15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wollmuth</surname><given-names>LP</given-names></name><name><surname>Kuner</surname><given-names>T</given-names></name><name><surname>Seeburg</surname><given-names>PH</given-names></name><etal></etal></person-group>:
<article-title>Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>1996</year>;<volume>491</volume>(<issue>Pt 3</issue>):<fpage>779</fpage>–<lpage>97</lpage>.
<pub-id pub-id-type="doi">10.1113/jphysiol.1996.sp021257</pub-id>
<!--<pub-id pub-id-type="pmcid">1158818</pub-id>-->
<pub-id pub-id-type="pmid">8815211</pub-id></mixed-citation>
</ref>
<ref id="ref-16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneggenburger</surname><given-names>R</given-names></name><name><surname>Ascher</surname><given-names>P</given-names></name></person-group>:
<article-title>Coupling of permeation and gating in an NMDA-channel pore mutant.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>1997</year>;<volume>18</volume>(<issue>1</issue>):<fpage>167</fpage>–<lpage>77</lpage>.
<pub-id pub-id-type="doi">10.1016/s0896-6273(01)80055-6</pub-id>
<pub-id pub-id-type="pmid">9010214</pub-id></mixed-citation>
</ref>
<ref id="ref-17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuo</surname><given-names>J</given-names></name><name><surname>de Jager</surname><given-names>PL</given-names></name><name><surname>Takahashi</surname><given-names>KA</given-names></name><etal></etal></person-group>:
<article-title>Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate receptor gene.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>1997</year>;<volume>388</volume>(<issue>6644</issue>):<fpage>769</fpage>–<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1038/42009</pub-id>
<pub-id pub-id-type="pmid">9285588</pub-id></mixed-citation>
</ref>
<ref id="ref-18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krupp</surname><given-names>JJ</given-names></name><name><surname>Vissel</surname><given-names>B</given-names></name><name><surname>Heinemann</surname><given-names>SF</given-names></name><etal></etal></person-group>:
<article-title>N-terminal domains in the NR2 subunit control desensitization of NMDA receptors.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>1998</year>;<volume>20</volume>(<issue>2</issue>):<fpage>317</fpage>–<lpage>27</lpage>.
<pub-id pub-id-type="doi">10.1016/S0896-6273(00)80459-6</pub-id>
<pub-id pub-id-type="pmid">9491992</pub-id></mixed-citation>
</ref>
<ref id="ref-19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Villarroel</surname><given-names>A</given-names></name><name><surname>Regalado</surname><given-names>MP</given-names></name><name><surname>Lerma</surname><given-names>J</given-names></name></person-group>:
<article-title>Glycine-independent NMDA receptor desensitization: localization of structural determinants.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>1998</year>;<volume>20</volume>(<issue>2</issue>):<fpage>329</fpage>–<lpage>39</lpage>.
<pub-id pub-id-type="doi">10.1016/S0896-6273(00)80460-2</pub-id>
<pub-id pub-id-type="pmid">9491993</pub-id></mixed-citation>
</ref>
<ref id="ref-20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Honse</surname><given-names>Y</given-names></name><name><surname>Karp</surname><given-names>BJ</given-names></name><etal></etal></person-group>:
<article-title>A site in the fourth membrane-associated domain of the
<italic>N</italic>-methyl-D-aspartate receptor regulates desensitization and ion channel gating.</article-title>
<source/><italic toggle="yes">J Biol Chem.</italic>
<year>2003</year>;<volume>278</volume>(<issue>1</issue>):<fpage>276</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M209486200</pub-id>
<pub-id pub-id-type="pmid">12414797</pub-id></mixed-citation>
</ref>
<ref id="ref-21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><etal></etal></person-group>:
<article-title>
<italic>De novo GRIN</italic> variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.</article-title>
<source/><italic toggle="yes">Hum Mutat.</italic>
<year>2019</year>; in press
<pub-id pub-id-type="doi">10.1002/humu.23895</pub-id>
<pub-id pub-id-type="pmid">31429998</pub-id></mixed-citation>
</ref>
<ref id="ref-22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dingledine</surname><given-names>R</given-names></name><name><surname>Borges</surname><given-names>K</given-names></name><name><surname>Bowie</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>The glutamate receptor ion channels.</article-title>
<source/><italic toggle="yes">Pharmacol Rev.</italic>
<year>1999</year>;<volume>51</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>61</lpage>.
<pub-id pub-id-type="pmid">10049997</pub-id></mixed-citation>
</ref>
<ref id="ref-23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Shieh</surname><given-names>C</given-names></name><name><surname>Swanger</surname><given-names>SA</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN1</italic> mutation associated with intellectual disability alters NMDA receptor trafficking and function.</article-title>
<source/><italic toggle="yes">J Hum Genet.</italic>
<year>2017</year>;<volume>62</volume>(<issue>6</issue>):<fpage>589</fpage>–<lpage>97</lpage>.
<pub-id pub-id-type="doi">10.1038/jhg.2017.19</pub-id>
<!--<pub-id pub-id-type="pmcid">5637523</pub-id>-->
<pub-id pub-id-type="pmid">28228639</pub-id></mixed-citation>
</ref>
<ref id="ref-24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gibb</surname><given-names>AJ</given-names></name><name><surname>Ogden</surname><given-names>KK</given-names></name><name><surname>McDaniel</surname><given-names>MJ</given-names></name><etal></etal></person-group>:
<article-title>A structurally derived model of subunit-dependent NMDA receptor function.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>2018</year>;<volume>596</volume>(<issue>17</issue>):<fpage>4057</fpage>–<lpage>89</lpage>.
<pub-id pub-id-type="doi">10.1113/JP276093</pub-id>
<!--<pub-id pub-id-type="pmcid">6117563</pub-id>-->
<pub-id pub-id-type="pmid">29917241</pub-id></mixed-citation>
</ref>
<ref id="ref-25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacDermott</surname><given-names>AB</given-names></name><name><surname>Mayer</surname><given-names>ML</given-names></name><name><surname>Westbrook</surname><given-names>GL</given-names></name><etal></etal></person-group>:
<article-title>NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>1986</year>;<volume>321</volume>(<issue>6069</issue>):<fpage>519</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1038/321519a0</pub-id>
<pub-id pub-id-type="pmid">3012362</pub-id></mixed-citation>
</ref>
<ref id="ref-26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneggenburger</surname><given-names>R</given-names></name></person-group>:
<article-title>Simultaneous measurement of Ca
<sup>2+</sup> influx and reversal potentials in recombinant
<italic>N</italic>-methyl-D-aspartate receptor channels.</article-title>
<source/><italic toggle="yes">Biophys J.</italic>
<year>1996</year>;<volume>70</volume>(<issue>5</issue>):<fpage>2165</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1016/S0006-3495(96)79782-5</pub-id>
<!--<pub-id pub-id-type="pmcid">1225191</pub-id>-->
<pub-id pub-id-type="pmid">9172740</pub-id></mixed-citation>
</ref>
<ref id="ref-27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Beck</surname><given-names>C</given-names></name><name><surname>Kuner</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>DRPEER: a motif in the extracellular vestibule conferring high Ca
<sup>2+</sup> flux rates in NMDA receptor channels.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>2002</year>;<volume>22</volume>(<issue>23</issue>):<fpage>10209</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-23-10209.2002</pub-id>
<pub-id pub-id-type="pmid">12451122</pub-id></mixed-citation>
</ref>
<ref id="ref-28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Heist</surname><given-names>EK</given-names></name><name><surname>Tsien</surname><given-names>RW</given-names></name></person-group>:
<article-title>Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>1998</year>;<volume>392</volume>(<issue>6672</issue>):<fpage>198</fpage>–<lpage>202</lpage>.
<pub-id pub-id-type="doi">10.1038/32448</pub-id>
<pub-id pub-id-type="pmid">9515967</pub-id></mixed-citation>
</ref>
<ref id="ref-29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bayer</surname><given-names>KU</given-names></name><name><surname>de Koninck</surname><given-names>P</given-names></name><name><surname>Leonard</surname><given-names>AS</given-names></name><etal></etal></person-group>:
<article-title>Interaction with the NMDA receptor locks CaMKII in an active conformation.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>2001</year>;<volume>411</volume>(<issue>6839</issue>):<fpage>801</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1038/35081080</pub-id>
<pub-id pub-id-type="pmid">11459059</pub-id></mixed-citation>
</ref>
<ref id="ref-30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herring</surname><given-names>BE</given-names></name><name><surname>Nicoll</surname><given-names>RA</given-names></name></person-group>:
<article-title>Long-Term Potentiation: From CaMKII to AMPA Receptor Trafficking.</article-title>
<source/><italic toggle="yes">Annu Rev Physiol.</italic>
<year>2016</year>;<volume>78</volume>:<fpage>351</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev-physiol-021014-071753</pub-id>
<pub-id pub-id-type="pmid">26863325</pub-id></mixed-citation>
</ref>
<ref id="ref-31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bender</surname><given-names>VA</given-names></name><name><surname>Bender</surname><given-names>KJ</given-names></name><name><surname>Brasier</surname><given-names>DJ</given-names></name><etal></etal></person-group>:
<article-title>Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>2006</year>;<volume>26</volume>(<issue>16</issue>):<fpage>4166</fpage>–<lpage>77</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0176-06.2006</pub-id>
<!--<pub-id pub-id-type="pmcid">3071735</pub-id>-->
<pub-id pub-id-type="pmid">16624937</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1007618">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sather</surname><given-names>W</given-names></name><name><surname>Dieudonné</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>JF</given-names></name><etal></etal></person-group>:
<article-title>Activation and desensitization of
<italic>N</italic>-methyl-D-aspartate receptors in nucleated outside-out patches from mouse neurones.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>1992</year>;<volume>450</volume>(<issue>1</issue>):<fpage>643</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1113/jphysiol.1992.sp019148</pub-id>
<!--<pub-id pub-id-type="pmcid">1176143</pub-id>-->
<pub-id pub-id-type="pmid">1359126</pub-id></mixed-citation>
</ref>
<ref id="ref-33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medina</surname><given-names>I</given-names></name><name><surname>Filippova</surname><given-names>N</given-names></name><name><surname>Charton</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>Calcium-dependent inactivation of heteromeric NMDA receptor-channels expressed in human embryonic kidney cells.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>1995</year>;<volume>482</volume>(<issue>Pt 3</issue>):<fpage>567</fpage>–<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1113/jphysiol.1995.sp020540</pub-id>
<!--<pub-id pub-id-type="pmcid">1157782</pub-id>-->
<pub-id pub-id-type="pmid">7537819</pub-id></mixed-citation>
</ref>
<ref id="ref-34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Price</surname><given-names>CJ</given-names></name><name><surname>Rintoul</surname><given-names>GL</given-names></name><name><surname>Baimbridge</surname><given-names>KG</given-names></name><etal></etal></person-group>:
<article-title>Inhibition of calcium-dependent NMDA receptor current rundown by calbindin-D
<sub>28k</sub>.</article-title>
<source/><italic toggle="yes">J Neurochem.</italic>
<year>1999</year>;<volume>72</volume>(<issue>2</issue>):<fpage>634</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0720634.x</pub-id>
<pub-id pub-id-type="pmid">9930735</pub-id></mixed-citation>
</ref>
<ref id="ref-35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erreger</surname><given-names>K</given-names></name><name><surname>Dravid</surname><given-names>SM</given-names></name><name><surname>Banke</surname><given-names>TG</given-names></name><etal></etal></person-group>:
<article-title>Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>2005</year>;<volume>563</volume>(<issue>Pt 2</issue>):<fpage>345</fpage>–<lpage>58</lpage>.
<pub-id pub-id-type="doi">10.1113/jphysiol.2004.080028</pub-id>
<!--<pub-id pub-id-type="pmcid">1665591</pub-id>-->
<pub-id pub-id-type="pmid">15649985</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1023899">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Raymond</surname><given-names>LA</given-names></name></person-group>:
<article-title>Subtype-dependence of NMDA receptor channel open probability.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>1999</year>;<volume>19</volume>(<issue>16</issue>):<fpage>6844</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-16-06844.1999</pub-id>
<!--<pub-id pub-id-type="pmcid">6782868</pub-id>-->
<pub-id pub-id-type="pmid">10436042</pub-id></mixed-citation>
</ref>
<ref id="ref-37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erreger</surname><given-names>K</given-names></name><name><surname>Geballe</surname><given-names>MT</given-names></name><name><surname>Kristensen</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing
<italic>N</italic>-methyl-D-aspartate glutamate receptors.</article-title>
<source/><italic toggle="yes">Mol Pharmacol.</italic>
<year>2007</year>;<volume>72</volume>(<issue>4</issue>):<fpage>907</fpage>–<lpage>20</lpage>.
<pub-id pub-id-type="doi">10.1124/mol.107.037333</pub-id>
<pub-id pub-id-type="pmid">17622578</pub-id></mixed-citation>
</ref>
<ref id="ref-38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vicini</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><etal></etal></person-group>:
<article-title>Functional and pharmacological differences between recombinant
<italic>N</italic>-methyl-D-aspartate receptors.</article-title>
<source/><italic toggle="yes">J Neurophysiol.</italic>
<year>1998</year>;<volume>79</volume>(<issue>2</issue>):<fpage>555</fpage>–<lpage>66</lpage>.
<pub-id pub-id-type="doi">10.1152/jn.1998.79.2.555</pub-id>
<pub-id pub-id-type="pmid">9463421</pub-id></mixed-citation>
</ref>
<ref id="ref-39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lester</surname><given-names>RA</given-names></name><name><surname>Clements</surname><given-names>JD</given-names></name><name><surname>Westbrook</surname><given-names>GL</given-names></name><etal></etal></person-group>:
<article-title>Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>1990</year>;<volume>346</volume>(<issue>6284</issue>):<fpage>565</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/346565a0</pub-id>
<pub-id pub-id-type="pmid">1974037</pub-id></mixed-citation>
</ref>
<ref id="ref-40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>P</given-names></name><name><surname>Ascher</surname><given-names>P</given-names></name><name><surname>Neyton</surname><given-names>J</given-names></name></person-group>:
<article-title>High-affinity zinc inhibition of NMDA NR1-NR2A receptors.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>1997</year>;<volume>17</volume>(<issue>15</issue>):<fpage>5711</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.17-15-05711.1997</pub-id>
<pub-id pub-id-type="pmid">9221770</pub-id></mixed-citation>
</ref>
<ref id="ref-41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Traynelis</surname><given-names>SF</given-names></name><name><surname>Burgess</surname><given-names>MF</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>1998</year>;<volume>18</volume>(<issue>16</issue>):<fpage>6163</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.18-16-06163.1998</pub-id>
<!--<pub-id pub-id-type="pmcid">6793196</pub-id>-->
<pub-id pub-id-type="pmid">9698310</pub-id></mixed-citation>
</ref>
<ref id="ref-42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rachline</surname><given-names>J</given-names></name><name><surname>Perin-Dureau</surname><given-names>F</given-names></name><name><surname>Le Goff</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>2005</year>;<volume>25</volume>(<issue>2</issue>):<fpage>308</fpage>–<lpage>17</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3967-04.2005</pub-id>
<!--<pub-id pub-id-type="pmcid">6725474</pub-id>-->
<pub-id pub-id-type="pmid">15647474</pub-id></mixed-citation>
</ref>
<ref id="ref-43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groc</surname><given-names>L</given-names></name><name><surname>Choquet</surname><given-names>D</given-names></name></person-group>:
<article-title>AMPA and NMDA glutamate receptor trafficking: Multiple roads for reaching and leaving the synapse.</article-title>
<source/><italic toggle="yes">Cell Tissue Res.</italic>
<year>2006</year>;<volume>326</volume>(<issue>2</issue>):<fpage>423</fpage>–<lpage>38</lpage>.
<pub-id pub-id-type="doi">10.1007/s00441-006-0254-9</pub-id>
<pub-id pub-id-type="pmid">16847641</pub-id></mixed-citation>
</ref>
<ref id="ref-44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petralia</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Hua</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Organization of NMDA receptors at extrasynaptic locations.</article-title>
<source/><italic toggle="yes">Neuroscience.</italic>
<year>2010</year>;<volume>167</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>87</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.01.022</pub-id>
<!--<pub-id pub-id-type="pmcid">2840201</pub-id>-->
<pub-id pub-id-type="pmid">20096331</pub-id></mixed-citation>
</ref>
<ref id="ref-45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanz-Clemente</surname><given-names>A</given-names></name><name><surname>Nicoll</surname><given-names>RA</given-names></name><name><surname>Roche</surname><given-names>KW</given-names></name></person-group>:
<article-title>Diversity in NMDA receptor composition: many regulators, many consequences.</article-title>
<source/><italic toggle="yes">Neuroscientist.</italic>
<year>2013</year>;<volume>19</volume>(<issue>1</issue>):<fpage>62</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1177/1073858411435129</pub-id>
<!--<pub-id pub-id-type="pmcid">3567917</pub-id>-->
<pub-id pub-id-type="pmid">22343826</pub-id></mixed-citation>
</ref>
<ref id="ref-46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic
<italic>N</italic>-methyl-D-aspartate receptor function and neuronal excitotoxicity.</article-title>
<source/><italic toggle="yes">J Biol Chem.</italic>
<year>2013</year>;<volume>288</volume>(<issue>33</issue>):<fpage>24151</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M113.482000</pub-id>
<!--<pub-id pub-id-type="pmcid">3745357</pub-id>-->
<pub-id pub-id-type="pmid">23839940</pub-id></mixed-citation>
</ref>
<ref id="ref-47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Won</surname><given-names>S</given-names></name><name><surname>Incontro</surname><given-names>S</given-names></name><name><surname>Nicoll</surname><given-names>RA</given-names></name><etal></etal></person-group>:
<article-title>PSD-95 stabilizes NMDA receptors by inducing the degradation of STEP61.</article-title>
<source/><italic toggle="yes">Proc Natl Acad Sci U S A.</italic>
<year>2016</year>;<volume>113</volume>(<issue>32</issue>):<fpage>E4736</fpage>-<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1609702113</pub-id>
<!--<pub-id pub-id-type="pmcid">4987792</pub-id>-->
<pub-id pub-id-type="pmid">27457929</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726578947">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delgado</surname><given-names>JY</given-names></name><name><surname>Fink</surname><given-names>AE</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name><etal></etal></person-group>:
<article-title>Rapid homeostatic downregulation of LTP by extrasynaptic GluN2B receptors.</article-title>
<source/><italic toggle="yes">J Neurophysiol.</italic>
<year>2018</year>;<volume>120</volume>(<issue>5</issue>):<fpage>2351</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1152/jn.00421.2018</pub-id>
<!--<pub-id pub-id-type="pmcid">6295522</pub-id>-->
<pub-id pub-id-type="pmid">30110236</pub-id></mixed-citation>
</ref>
<ref id="ref-49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hardingham</surname><given-names>GE</given-names></name><name><surname>Fukunaga</surname><given-names>Y</given-names></name><name><surname>Bading</surname><given-names>H</given-names></name></person-group>:
<article-title>Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways.</article-title>
<source/><italic toggle="yes">Nat Neurosci.</italic>
<year>2002</year>;<volume>5</volume>(<issue>5</issue>):<fpage>405</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.1038/nn835</pub-id>
<pub-id pub-id-type="pmid">11953750</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1006391">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martel</surname><given-names>MA</given-names></name><name><surname>Wyllie</surname><given-names>DJ</given-names></name><name><surname>Hardingham</surname><given-names>GE</given-names></name></person-group>:
<article-title>In developing hippocampal neurons, NR2B-containing
<italic>N</italic>-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death.</article-title>
<source/><italic toggle="yes">Neuroscience.</italic>
<year>2009</year>;<volume>158</volume>(<issue>1</issue>):<fpage>334</fpage>–<lpage>43</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.01.080</pub-id>
<!--<pub-id pub-id-type="pmcid">2635533</pub-id>-->
<pub-id pub-id-type="pmid">18378405</pub-id></mixed-citation>
</ref>
<ref id="ref-51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soriano</surname><given-names>FX</given-names></name><name><surname>Hardingham</surname><given-names>GE</given-names></name></person-group>:
<article-title>Compartmentalized NMDA receptor signalling to survival and death.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>2007</year>;<volume>584</volume>(<issue>Pt 2</issue>):<fpage>381</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1113/jphysiol.2007.138875</pub-id>
<!--<pub-id pub-id-type="pmcid">2277150</pub-id>-->
<pub-id pub-id-type="pmid">17690142</pub-id></mixed-citation>
</ref>
<ref id="ref-52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hardingham</surname><given-names>GE</given-names></name></person-group>:
<article-title>Coupling of the NMDA receptor to neuroprotective and neurodestructive events.</article-title>
<source/><italic toggle="yes">Biochem Soc Trans.</italic>
<year>2009</year>;<volume>37</volume>(<issue>Pt 6</issue>):<fpage>1147</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1042/BST0371147</pub-id>
<!--<pub-id pub-id-type="pmcid">2837198</pub-id>-->
<pub-id pub-id-type="pmid">19909238</pub-id></mixed-citation>
</ref>
<ref id="ref-53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monyer</surname><given-names>H</given-names></name><name><surname>Burnashev</surname><given-names>N</given-names></name><name><surname>Laurie</surname><given-names>DJ</given-names></name><etal></etal></person-group>:
<article-title>Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>1994</year>;<volume>12</volume>(<issue>3</issue>):<fpage>529</fpage>–<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1016/0896-6273(94)90210-0</pub-id>
<pub-id pub-id-type="pmid">7512349</pub-id></mixed-citation>
</ref>
<ref id="ref-54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hatten</surname><given-names>ME</given-names></name></person-group>:
<article-title>Central nervous system neuronal migration.</article-title>
<source/><italic toggle="yes">Annu Rev Neurosci.</italic>
<year>1999</year>;<volume>22</volume>:<fpage>511</fpage>–<lpage>39</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev.neuro.22.1.511</pub-id>
<pub-id pub-id-type="pmid">10202547</pub-id></mixed-citation>
</ref>
<ref id="ref-55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medina</surname><given-names>AE</given-names></name><name><surname>Liao</surname><given-names>DS</given-names></name><name><surname>Mower</surname><given-names>AF</given-names></name><etal></etal></person-group>:
<article-title>Do NMDA receptor kinetics regulate the end of critical periods of plasticity?</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>2001</year>;<volume>32</volume>(<issue>4</issue>):<fpage>553</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/s0896-6273(01)00514-1</pub-id>
<pub-id pub-id-type="pmid">11719195</pub-id></mixed-citation>
</ref>
<ref id="ref-56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumas</surname><given-names>TC</given-names></name></person-group>:
<article-title>Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative learning.</article-title>
<source/><italic toggle="yes">Prog Neurobiol.</italic>
<year>2005</year>;<volume>76</volume>(<issue>3</issue>):<fpage>189</fpage>–<lpage>211</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2005.08.002</pub-id>
<pub-id pub-id-type="pmid">16181726</pub-id></mixed-citation>
</ref>
<ref id="ref-57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monaco</surname><given-names>SA</given-names></name><name><surname>Gulchina</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name></person-group>:
<article-title>NR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders.</article-title>
<source/><italic toggle="yes">Neurosci Biobehav Rev.</italic>
<year>2015</year>;<volume>56</volume>:<fpage>127</fpage>–<lpage>38</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.06.022</pub-id>
<!--<pub-id pub-id-type="pmcid">4567400</pub-id>-->
<pub-id pub-id-type="pmid">26143512</pub-id></mixed-citation>
</ref>
<ref id="ref-58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wyllie</surname><given-names>DJ</given-names></name><name><surname>Livesey</surname><given-names>MR</given-names></name><name><surname>Hardingham</surname><given-names>GE</given-names></name></person-group>:
<article-title>Influence of GluN2 subunit identity on NMDA receptor function.</article-title>
<source/><italic toggle="yes">Neuropharmacology.</italic>
<year>2013</year>;<volume>74</volume>:<fpage>4</fpage>–<lpage>17</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.01.016</pub-id>
<!--<pub-id pub-id-type="pmcid">3778433</pub-id>-->
<pub-id pub-id-type="pmid">23376022</pub-id></mixed-citation>
</ref>
<ref id="ref-59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Mishina</surname><given-names>M</given-names></name></person-group>:
<article-title>Structure and function of the NMDA receptor channel.</article-title>
<source/><italic toggle="yes">Neuropharmacology.</italic>
<year>1995</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1219</fpage>–<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1016/0028-3908(95)00109-j</pub-id>
<pub-id pub-id-type="pmid">8570021</pub-id></mixed-citation>
</ref>
<ref id="ref-60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akazawa</surname><given-names>C</given-names></name><name><surname>Shigemoto</surname><given-names>R</given-names></name><name><surname>Bessho</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.</article-title>
<source/><italic toggle="yes">J Comp Neurol.</italic>
<year>1994</year>;<volume>347</volume>(<issue>1</issue>):<fpage>150</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1002/cne.903470112</pub-id>
<pub-id pub-id-type="pmid">7798379</pub-id></mixed-citation>
</ref>
<ref id="ref-61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Constantine-Paton</surname><given-names>M</given-names></name></person-group>:
<article-title>Activity-dependent induction of tonic calcineurin activity mediates a rapid developmental downregulation of NMDA receptor currents.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>2000</year>;<volume>28</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.1016/s0896-6273(00)00089-1</pub-id>
<pub-id pub-id-type="pmid">11086987</pub-id></mixed-citation>
</ref>
<ref id="ref-62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Zundert</surname><given-names>B</given-names></name><name><surname>Yoshii</surname><given-names>A</given-names></name><name><surname>Constantine-Paton</surname><given-names>M</given-names></name></person-group>:
<article-title>Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal.</article-title>
<source/><italic toggle="yes">Trends Neurosci.</italic>
<year>2004</year>;<volume>27</volume>(<issue>7</issue>):<fpage>428</fpage>–<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1016/j.tins.2004.05.010</pub-id>
<pub-id pub-id-type="pmid">15219743</pub-id></mixed-citation>
</ref>
<ref id="ref-63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKay</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>McQueen</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences.</article-title>
<source/><italic toggle="yes">Cell Rep.</italic>
<year>2018</year>;<volume>25</volume>(<issue>4</issue>):<fpage>841</fpage>–<lpage>851.e4</lpage>.
<pub-id pub-id-type="doi">10.1016/j.celrep.2018.09.089</pub-id>
<!--<pub-id pub-id-type="pmcid">6218242</pub-id>-->
<pub-id pub-id-type="pmid">30355491</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734278718">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bar-Shira</surname><given-names>O</given-names></name><name><surname>Maor</surname><given-names>R</given-names></name><name><surname>Chechik</surname><given-names>G</given-names></name></person-group>:
<article-title>Gene Expression Switching of Receptor Subunits in Human Brain Development.</article-title>
<source/><italic toggle="yes">PLoS Comput Biol.</italic>
<year>2015</year>;<volume>11</volume>(<issue>12</issue>):<fpage>e1004559</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004559</pub-id>
<!--<pub-id pub-id-type="pmcid">4670163</pub-id>-->
<pub-id pub-id-type="pmid">26636753</pub-id></mixed-citation>
</ref>
<ref id="ref-65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Russell</surname><given-names>SL</given-names></name><name><surname>Shen</surname><given-names>YM</given-names></name><etal></etal></person-group>:
<article-title>Developmental switch in the expression of NMDA receptors occurs
<italic>in vivo</italic> and
<italic>in vitro</italic>.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>1993</year>;<volume>10</volume>(<issue>2</issue>):<fpage>267</fpage>–<lpage>78</lpage>.
<pub-id pub-id-type="doi">10.1016/0896-6273(93)90317-k</pub-id>
<pub-id pub-id-type="pmid">8439412</pub-id></mixed-citation>
</ref>
<ref id="ref-66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barth</surname><given-names>AL</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name></person-group>:
<article-title>NMDAR EPSC kinetics do not regulate the critical period for LTP at thalamocortical synapses.</article-title>
<source/><italic toggle="yes">Nat Neurosci.</italic>
<year>2001</year>;<volume>4</volume>(<issue>3</issue>):<fpage>235</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/85070</pub-id>
<pub-id pub-id-type="pmid">11224537</pub-id></mixed-citation>
</ref>
<ref id="ref-67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group>:
<article-title>Communication between the synapse and the nucleus in neuronal development, plasticity, and disease.</article-title>
<source/><italic toggle="yes">Annu Rev Cell Dev Biol.</italic>
<year>2008</year>;<volume>24</volume>:<fpage>183</fpage>–<lpage>209</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev.cellbio.24.110707.175235</pub-id>
<!--<pub-id pub-id-type="pmcid">2709812</pub-id>-->
<pub-id pub-id-type="pmid">18616423</pub-id></mixed-citation>
</ref>
<ref id="ref-68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hall</surname><given-names>BJ</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name></person-group>:
<article-title>NR2B signaling regulates the development of synaptic AMPA receptor current.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>2007</year>;<volume>27</volume>(<issue>49</issue>):<fpage>13446</fpage>–<lpage>56</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3793-07.2007</pub-id>
<!--<pub-id pub-id-type="pmcid">6673095</pub-id>-->
<pub-id pub-id-type="pmid">18057203</pub-id></mixed-citation>
</ref>
<ref id="ref-69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kutsuwada</surname><given-names>T</given-names></name><name><surname>Sakimura</surname><given-names>K</given-names></name><name><surname>Manabe</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>1996</year>;<volume>16</volume>(<issue>2</issue>):<fpage>333</fpage>–<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1016/s0896-6273(00)80051-3</pub-id>
<pub-id pub-id-type="pmid">8789948</pub-id></mixed-citation>
</ref>
<ref id="ref-70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>YP</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Dube</surname><given-names>GR</given-names></name><etal></etal></person-group>:
<article-title>Genetic enhancement of learning and memory in mice.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>1999</year>;<volume>401</volume>(<issue>6748</issue>):<fpage>63</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/43432</pub-id>
<pub-id pub-id-type="pmid">10485705</pub-id></mixed-citation>
</ref>
<ref id="ref-71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Myers</surname><given-names>SJ</given-names></name><etal></etal></person-group>:
<article-title>Human
<italic>GRIN2B</italic> variants in neurodevelopmental disorders.</article-title>
<source/><italic toggle="yes">J Pharmacol Sci.</italic>
<year>2016</year>;<volume>132</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jphs.2016.10.002</pub-id>
<!--<pub-id pub-id-type="pmcid">5125235</pub-id>-->
<pub-id pub-id-type="pmid">27818011</pub-id></mixed-citation>
</ref>
<ref id="ref-72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>XiangWei</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name></person-group>:
<article-title>
<italic>De Novo</italic> Mutations and Rare Variants Occurring in NMDA Receptors.</article-title>
<source/><italic toggle="yes">Curr Opin Physiol.</italic>
<year>2018</year>;<volume>2</volume>:<fpage>27</fpage>–<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cophys.2017.12.013</pub-id>
<!--<pub-id pub-id-type="pmcid">5945193</pub-id>-->
<pub-id pub-id-type="pmid">29756080</pub-id></mixed-citation>
</ref>
<ref id="ref-73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>KB</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Functional analysis of a
<italic>de novo GRIN2A</italic> missense mutation associated with early-onset epileptic encephalopathy.</article-title>
<source/><italic toggle="yes">Nat Commun.</italic>
<year>2014</year>;<volume>5</volume>:<fpage>3251</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms4251</pub-id>
<!--<pub-id pub-id-type="pmcid">3934797</pub-id>-->
<pub-id pub-id-type="pmid">24504326</pub-id></mixed-citation>
</ref>
<ref id="ref-74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemke</surname><given-names>JR</given-names></name><name><surname>Geider</surname><given-names>K</given-names></name><name><surname>Helbig</surname><given-names>KL</given-names></name><etal></etal></person-group>:
<article-title>Delineating the
<italic>GRIN1</italic> phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy.</article-title>
<source/><italic toggle="yes">Neurology.</italic>
<year>2016</year>;<volume>86</volume>(<issue>23</issue>):<fpage>2171</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002740</pub-id>
<!--<pub-id pub-id-type="pmcid">4898312</pub-id>-->
<pub-id pub-id-type="pmid">27164704</pub-id></mixed-citation>
</ref>
<ref id="ref-75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Endele</surname><given-names>S</given-names></name><name><surname>Rosenberger</surname><given-names>G</given-names></name><name><surname>Geider</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Mutations in
<italic>GRIN2A</italic> and
<italic>GRIN2B</italic> encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.</article-title>
<source/><italic toggle="yes">Nat Genet.</italic>
<year>2010</year>;<volume>42</volume>(<issue>11</issue>):<fpage>1021</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.677</pub-id>
<pub-id pub-id-type="pmid">20890276</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/6705956">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reutlinger</surname><given-names>C</given-names></name><name><surname>Helbig</surname><given-names>I</given-names></name><name><surname>Gawelczyk</surname><given-names>B</given-names></name><etal></etal></person-group>:
<article-title>Deletions in 16p13 including
<italic>GRIN2A</italic> in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region.</article-title>
<source/><italic toggle="yes">Epilepsia.</italic>
<year>2010</year>;<volume>51</volume>(<issue>9</issue>):<fpage>1870</fpage>–<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02555.x</pub-id>
<pub-id pub-id-type="pmid">20384727</pub-id></mixed-citation>
</ref>
<ref id="ref-77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burnashev</surname><given-names>N</given-names></name><name><surname>Szepetowski</surname><given-names>P</given-names></name></person-group>:
<article-title>NMDA receptor subunit mutations in neurodevelopmental disorders.</article-title>
<source/><italic toggle="yes">Curr Opin Pharmacol.</italic>
<year>2015</year>;<volume>20</volume>:<fpage>73</fpage>–<lpage>82</lpage>.
<pub-id pub-id-type="doi">10.1016/j.coph.2014.11.008</pub-id>
<pub-id pub-id-type="pmid">25498981</pub-id></mixed-citation>
</ref>
<ref id="ref-78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Low</surname><given-names>CM</given-names></name><name><surname>Moody</surname><given-names>OA</given-names></name><etal></etal></person-group>:
<article-title>Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases.</article-title>
<source/><italic toggle="yes">Mol Pharmacol.</italic>
<year>2015</year>;<volume>88</volume>(<issue>1</issue>):<fpage>203</fpage>–<lpage>17</lpage>.
<pub-id pub-id-type="doi">10.1124/mol.115.097998</pub-id>
<!--<pub-id pub-id-type="pmcid">4468639</pub-id>-->
<pub-id pub-id-type="pmid">25904555</pub-id></mixed-citation>
</ref>
<ref id="ref-79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sibarov</surname><given-names>DA</given-names></name><name><surname>Bruneau</surname><given-names>N</given-names></name><name><surname>Antonov</surname><given-names>SM</given-names></name><etal></etal></person-group>:
<article-title>Functional Properties of Human NMDA Receptors Associated with Epilepsy-Related Mutations of GluN2A Subunit.</article-title>
<source/><italic toggle="yes">Front Cell Neurosci.</italic>
<year>2017</year>;<volume>11</volume>:<fpage>155</fpage>.
<pub-id pub-id-type="doi">10.3389/fncel.2017.00155</pub-id>
<!--<pub-id pub-id-type="pmcid">5447064</pub-id>-->
<pub-id pub-id-type="pmid">28611597</pub-id></mixed-citation>
</ref>
<ref id="ref-80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fedele</surname><given-names>L</given-names></name><name><surname>Newcombe</surname><given-names>J</given-names></name><name><surname>Topf</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties.</article-title>
<source/><italic toggle="yes">Nat Commun.</italic>
<year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>957</fpage>.
<pub-id pub-id-type="doi">10.1038/s41467-018-02927-4</pub-id>
<!--<pub-id pub-id-type="pmcid">5840332</pub-id>-->
<pub-id pub-id-type="pmid">29511171</pub-id></mixed-citation>
</ref>
<ref id="ref-81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Traynelis</surname><given-names>J</given-names></name><name><surname>Silk</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal></etal></person-group>:
<article-title>Optimizing genomic medicine in epilepsy through a gene-customized approach to missense variant interpretation.</article-title>
<source/><italic toggle="yes">Genome Res.</italic>
<year>2017</year>;<volume>27</volume>(<issue>10</issue>):<fpage>1715</fpage>–<lpage>29</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.226589.117</pub-id>
<!--<pub-id pub-id-type="pmcid">5630035</pub-id>-->
<pub-id pub-id-type="pmid">28864458</pub-id></mixed-citation>
</ref>
<ref id="ref-82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanger</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains.</article-title>
<source/><italic toggle="yes">Am J Hum Genet.</italic>
<year>2016</year>;<volume>99</volume>(<issue>6</issue>):<fpage>1261</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.10.002</pub-id>
<!--<pub-id pub-id-type="pmcid">5142120</pub-id>-->
<pub-id pub-id-type="pmid">27839871</pub-id></mixed-citation>
</ref>
<ref id="ref-83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogden</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Swanger</surname><given-names>SA</given-names></name><etal></etal></person-group>:
<article-title>Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.</article-title>
<source/><italic toggle="yes">PLoS Genet.</italic>
<year>2017</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e1006536</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1006536</pub-id>
<!--<pub-id pub-id-type="pmcid">5240934</pub-id>-->
<pub-id pub-id-type="pmid">28095420</pub-id></mixed-citation>
</ref>
<ref id="ref-84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Platzer</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Schütz</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2B</italic> encephalopathy: Novel findings on phenotype, variant clustering, functional consequences and treatment aspects.</article-title>
<source/><italic toggle="yes">J Med Genet.</italic>
<year>2017</year>;<volume>54</volume>(<issue>7</issue>):<fpage>460</fpage>–<lpage>70</lpage>.
<pub-id pub-id-type="doi">10.1136/jmedgenet-2016-104509</pub-id>
<!--<pub-id pub-id-type="pmcid">5656050</pub-id>-->
<pub-id pub-id-type="pmid">28377535</pub-id></mixed-citation>
</ref>
<ref id="ref-85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strehlow</surname><given-names>V</given-names></name><name><surname>Heyne</surname><given-names>HO</given-names></name><name><surname>Vlaskamp</surname><given-names>DR</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2A</italic>-related disorders: Genotype and functional consequence predict phenotype.</article-title>
<source/><italic toggle="yes">Brain.</italic>
<year>2019</year>;<volume>142</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1093/brain/awy304</pub-id>
<!--<pub-id pub-id-type="pmcid">6308310</pub-id>-->
<pub-id pub-id-type="pmid">30544257</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734628231">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernández-Marmiesse</surname><given-names>A</given-names></name><name><surname>Kusumoto</surname><given-names>H</given-names></name><name><surname>Rekarte</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>A novel missense mutation in
<italic>GRIN2A</italic> causes a nonepileptic neurodevelopmental disorder.</article-title>
<source/><italic toggle="yes">Mov Disord.</italic>
<year>2018</year>;<volume>33</volume>(<issue>6</issue>):<fpage>992</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1002/mds.27315</pub-id>
<!--<pub-id pub-id-type="pmcid">6105539</pub-id>-->
<pub-id pub-id-type="pmid">29644724</pub-id></mixed-citation>
</ref>
<ref id="ref-87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Ortiz-Gonzalez</surname><given-names>XR</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2D</italic> Recurrent
<italic>De Novo</italic> Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers.</article-title>
<source/><italic toggle="yes">Am J Hum Genet.</italic>
<year>2016</year>;<volume>99</volume>(<issue>4</issue>):<fpage>802</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.07.013</pub-id>
<!--<pub-id pub-id-type="pmcid">5065652</pub-id>-->
<pub-id pub-id-type="pmid">27616483</pub-id></mixed-citation>
</ref>
<ref id="ref-88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fry</surname><given-names>AE</given-names></name><name><surname>Fawcett</surname><given-names>KA</given-names></name><name><surname>Zelnik</surname><given-names>N</given-names></name><etal></etal></person-group>:
<article-title>
<italic>De novo</italic> mutations in
<italic>GRIN1</italic> cause extensive bilateral polymicrogyria.</article-title>
<source/><italic toggle="yes">Brain.</italic>
<year>2018</year>;<volume>141</volume>(<issue>3</issue>):<fpage>698</fpage>–<lpage>712</lpage>.
<pub-id pub-id-type="doi">10.1093/brain/awx358</pub-id>
<!--<pub-id pub-id-type="pmcid">5837214</pub-id>-->
<pub-id pub-id-type="pmid">29365063</pub-id></mixed-citation>
</ref>
<ref id="ref-89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pierson</surname><given-names>TM</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Marsh</surname><given-names>ED</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2A</italic> mutation and early-onset epileptic encephalopathy: Personalized therapy with memantine.</article-title>
<source/><italic toggle="yes">Ann Clin Transl Neurol.</italic>
<year>2014</year>;<volume>1</volume>(<issue>3</issue>):<fpage>190</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1002/acn3.39</pub-id>
<!--<pub-id pub-id-type="pmcid">4019449</pub-id>-->
<pub-id pub-id-type="pmid">24839611</pub-id></mixed-citation>
</ref>
<ref id="ref-90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Tankovic</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>PB</given-names></name><etal></etal></person-group>:
<article-title>Functional Evaluation of a
<italic>De Novo GRIN2A</italic> Mutation Identified in a Patient with Profound Global Developmental Delay and Refractory Epilepsy.</article-title>
<source/><italic toggle="yes">Mol Pharmacol.</italic>
<year>2017</year>;<volume>91</volume>(<issue>4</issue>):<fpage>317</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1124/mol.116.106781</pub-id>
<!--<pub-id pub-id-type="pmcid">5363715</pub-id>-->
<pub-id pub-id-type="pmid">28126851</pub-id></mixed-citation>
</ref>
<ref id="ref-91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>JB</given-names></name><name><surname>Leng</surname><given-names>X</given-names></name><name><surname>Gochman</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>A conserved glycine harboring disease-associated mutations permits NMDA receptor slow deactivation and high Ca
<sup>2+</sup> permeability.</article-title>
<source/><italic toggle="yes">Nat Commun.</italic>
<year>2018</year>;<volume>9</volume>(<issue>4</issue>): 3748.
<pub-id pub-id-type="doi">10.1038/s41467-018-06145-w</pub-id>
<!--<pub-id pub-id-type="pmcid">6138751</pub-id>-->
<pub-id pub-id-type="pmid">30217972</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734019209">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marwick</surname><given-names>KF</given-names></name><name><surname>Hansen</surname><given-names>KB</given-names></name><name><surname>Skehel</surname><given-names>PA</given-names></name><etal></etal></person-group>:
<article-title>Functional assessment of triheteromeric NMDA receptors containing a human variant associated with epilepsy.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>2019</year>;<volume>597</volume>(<issue>6</issue>):<fpage>1691</fpage>–<lpage>704</lpage>.
<pub-id pub-id-type="doi">10.1113/JP277292</pub-id>
<!--<pub-id pub-id-type="pmcid">6418762</pub-id>-->
<pub-id pub-id-type="pmid">30604514</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/734757979">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>XX</given-names></name><name><surname>Liu</surname><given-names>XR</given-names></name><name><surname>Fan</surname><given-names>CY</given-names></name><etal></etal></person-group>:
<article-title>Functional Investigation of a
<italic>GRIN2A</italic> Variant Associated with Rolandic Epilepsy.</article-title>
<source/><italic toggle="yes">Neurosci Bull.</italic>
<year>2018</year>;<volume>34</volume>(<issue>2</issue>):<fpage>237</fpage>–<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1007/s12264-017-0182-6</pub-id>
<!--<pub-id pub-id-type="pmcid">5856713</pub-id>-->
<pub-id pub-id-type="pmid">28936771</pub-id></mixed-citation>
</ref>
<ref id="ref-94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Maussion</surname><given-names>G</given-names></name><name><surname>Jefri</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Disruption of
<italic>GRIN2B</italic> Impairs Differentiation in Human Neurons.</article-title>
<source/><italic toggle="yes">Stem Cell Reports.</italic>
<year>2018</year>;<volume>11</volume>(<issue>1</issue>):<fpage>183</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1016/j.stemcr.2018.05.018</pub-id>
<!--<pub-id pub-id-type="pmcid">6067152</pub-id>-->
<pub-id pub-id-type="pmid">29937144</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/733506834">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>McDaniel</surname><given-names>MJ</given-names></name><etal></etal></person-group>:
<article-title>The GluN2B-Glu413Gly NMDA receptor variant arising from a
<italic>de novo GRIN2B</italic> mutation promotes ligand-unbinding and domain opening.</article-title>
<source/><italic toggle="yes">Proteins.</italic>
<year>2018</year>;<volume>86</volume>(<issue>12</issue>):<fpage>1265</fpage>–<lpage>76</lpage>.
<pub-id pub-id-type="doi">10.1002/prot.25595</pub-id>
<!--<pub-id pub-id-type="pmcid">6774441</pub-id>-->
<pub-id pub-id-type="pmid">30168177</pub-id></mixed-citation>
</ref>
<ref id="ref-96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soto</surname><given-names>D</given-names></name><name><surname>Olivella</surname><given-names>M</given-names></name><name><surname>Grau</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>l-Serine dietary supplementation is associated with clinical improvement of loss-of-function
<italic>GRIN2B</italic>-related pediatric encephalopathy.</article-title>
<source/><italic toggle="yes">Sci Signal.</italic>
<year>2019</year>;<volume>12</volume>(<issue>586</issue>):<fpage>eaaw0936</fpage>.
<pub-id pub-id-type="doi">10.1126/scisignal.aaw0936</pub-id>
<pub-id pub-id-type="pmid">31213567</pub-id></mixed-citation>
</ref>
<ref id="ref-97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>XiangWei</surname><given-names>W</given-names></name><name><surname>Kannan</surname><given-names>V</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Heterogeneous Clinical and Functional Features of
<italic>GRIN2D</italic>-related Developmental and Epileptic Encephalopathy.</article-title>
<source/><italic toggle="yes">Brain.</italic>
<year>2019</year>;<volume>142</volume>(<issue>10</issue>):<fpage>3009</fpage>–<lpage>3027</lpage>.
<pub-id pub-id-type="doi">10.1093/brain/awz232</pub-id>
<!--<pub-id pub-id-type="pmcid">6763743</pub-id>-->
<pub-id pub-id-type="pmid">31504254</pub-id></mixed-citation>
</ref>
<ref id="ref-98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vyklicky</surname><given-names>V</given-names></name><name><surname>Krausova</surname><given-names>B</given-names></name><name><surname>Cerny</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title> Surface Expression, Function, and Pharmacology of Disease-Associated Mutations in the Membrane Domain of the Human GluN2B Subunit.</article-title>
<source/><italic toggle="yes">Front Mol Neurosci.</italic>
<year>2018</year>;<volume>11</volume>:<fpage>110</fpage>.
<pub-id pub-id-type="doi">10.3389/fnmol.2018.00110</pub-id>
<!--<pub-id pub-id-type="pmcid">5897658</pub-id>-->
<pub-id pub-id-type="pmid">29681796</pub-id></mixed-citation>
</ref>
<ref id="ref-99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carvill</surname><given-names>GL</given-names></name><name><surname>Regan</surname><given-names>BM</given-names></name><name><surname>Yendle</surname><given-names>SC</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2A</italic> mutations cause epilepsy-aphasia spectrum disorders.</article-title>
<source/><italic toggle="yes">Nat Genet.</italic>
<year>2013</year>;<volume>45</volume>(<issue>9</issue>):<fpage>1073</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.2727</pub-id>
<!--<pub-id pub-id-type="pmcid">3868952</pub-id>-->
<pub-id pub-id-type="pmid">23933818</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718071376">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemke</surname><given-names>JR</given-names></name><name><surname>Lal</surname><given-names>D</given-names></name><name><surname>Reinthaler</surname><given-names>EM</given-names></name><etal></etal></person-group>:
<article-title>Mutations in
<italic>GRIN2A</italic> cause idiopathic focal epilepsy with rolandic spikes.</article-title>
<source/><italic toggle="yes">Nat Genet.</italic>
<year>2013</year>;<volume>45</volume>(<issue>9</issue>):<fpage>1067</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.2728</pub-id>
<!--<pub-id pub-id-type="pmcid">3868952</pub-id>-->
<pub-id pub-id-type="pmid">23933819</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718071375">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lesca</surname><given-names>G</given-names></name><name><surname>Rudolf</surname><given-names>G</given-names></name><name><surname>Bruneau</surname><given-names>N</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2A</italic> mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.</article-title>
<source/><italic toggle="yes">Nat Genet.</italic>
<year>2013</year>;<volume>45</volume>(<issue>9</issue>):<fpage>1061</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.2726</pub-id>
<pub-id pub-id-type="pmid">23933820</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718071374">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salmi</surname><given-names>M</given-names></name><name><surname>Bolbos</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Transient microstructural brain anomalies and epileptiform discharges in mice defective for epilepsy and language-related NMDA receptor subunit gene
<italic>Grin2a</italic>.</article-title>
<source/><italic toggle="yes">Epilepsia.</italic>
<year>2018</year>;<volume>59</volume>(<issue>10</issue>):<fpage>1919</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1111/epi.14543</pub-id>
<pub-id pub-id-type="pmid">30146685</pub-id></mixed-citation>
</ref>
<ref id="ref-103">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemke</surname><given-names>JR</given-names></name><name><surname>Hendrickx</surname><given-names>R</given-names></name><name><surname>Geider</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>
<italic>GRIN2B</italic> mutations in west syndrome and intellectual disability with focal epilepsy.</article-title>
<source/><italic toggle="yes">Ann Neurol.</italic>
<year>2014</year>;<volume>75</volume>(<issue>1</issue>):<fpage>147</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1002/ana.24073</pub-id>
<!--<pub-id pub-id-type="pmcid">4223934</pub-id>-->
<pub-id pub-id-type="pmid">24272827</pub-id></mixed-citation>
</ref>
<ref id="ref-104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kenny</surname><given-names>EM</given-names></name><name><surname>Cormican</surname><given-names>P</given-names></name><name><surname>Furlong</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders.</article-title>
<source/><italic toggle="yes">Mol Psychiatry.</italic>
<year>2014</year>;<volume>19</volume>(<issue>8</issue>):<fpage>872</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/mp.2013.127</pub-id>
<pub-id pub-id-type="pmid">24126926</pub-id></mixed-citation>
</ref>
<ref id="ref-105">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Deriziotis</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Exome sequencing in sporadic autism spectrum disorders identifies severe
<italic>de novo</italic> mutations.</article-title>
<source/><italic toggle="yes">Nat Genet.</italic>
<year>2011</year>;<volume>43</volume>(<issue>6</issue>):<fpage>585</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.835</pub-id>
<!--<pub-id pub-id-type="pmcid">3115696</pub-id>-->
<pub-id pub-id-type="pmid">21572417</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/10819956">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-106">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>DR</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Holyoak</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Three rare diseases in one Sib pair:
<italic>RAI1, PCK1, GRIN2B</italic> mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity.</article-title>
<source/><italic toggle="yes">Mol Genet Metab.</italic>
<year>2014</year>;<volume>113</volume>(<issue>3</issue>):<fpage>161</fpage>–<lpage>70</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymgme.2014.04.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4219933</pub-id>-->
<pub-id pub-id-type="pmid">24863970</pub-id></mixed-citation>
</ref>
<ref id="ref-107">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Ligt</surname><given-names>J</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>van Bon</surname><given-names>BW</given-names></name><etal></etal></person-group>:
<article-title>Diagnostic exome sequencing in persons with severe intellectual disability.</article-title>
<source/><italic toggle="yes">N Engl J Med.</italic>
<year>2012</year>;<volume>367</volume>(<issue>20</issue>):<fpage>1921</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id>
<pub-id pub-id-type="pmid">23033978</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717959021">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stessman</surname><given-names>HA</given-names></name><name><surname>Xiong</surname><given-names>B</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><etal></etal></person-group>:
<article-title>Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases.</article-title>
<source/><italic toggle="yes">Nat Genet.</italic>
<year>2017</year>;<volume>49</volume>(<issue>4</issue>):<fpage>515</fpage>–<lpage>26</lpage>.
<pub-id pub-id-type="doi">10.1038/ng.3792</pub-id>
<!--<pub-id pub-id-type="pmcid">5374041</pub-id>-->
<pub-id pub-id-type="pmid">28191889</pub-id></mixed-citation>
</ref>
<ref id="ref-109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Stülpnagel</surname><given-names>C</given-names></name><name><surname>Ensslen</surname><given-names>M</given-names></name><name><surname>Møller</surname><given-names>RS</given-names></name><etal></etal></person-group>:
<article-title>Epilepsy in patients with
<italic>GRIN2A</italic> alterations: Genetics, neurodevelopment, epileptic phenotype and response to anticonvulsive drugs.</article-title>
<source/><italic toggle="yes">Eur J Paediatr Neurol.</italic>
<year>2017</year>;<volume>21</volume>(<issue>3</issue>):<fpage>530</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejpn.2017.01.001</pub-id>
<pub-id pub-id-type="pmid">28109652</pub-id></mixed-citation>
</ref>
<ref id="ref-110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boutry-Kryza</surname><given-names>N</given-names></name><name><surname>Labalme</surname><given-names>A</given-names></name><name><surname>Ville</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Molecular characterization of a cohort of 73 patients with infantile spasms syndrome.</article-title>
<source/><italic toggle="yes">Eur J Med Genet.</italic>
<year>2015</year>;<volume>58</volume>(<issue>2</issue>):<fpage>51</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejmg.2014.11.007</pub-id>
<pub-id pub-id-type="pmid">25497044</pub-id></mixed-citation>
</ref>
<ref id="ref-111">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarabeux</surname><given-names>J</given-names></name><name><surname>Kebir</surname><given-names>O</given-names></name><name><surname>Gauthier</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia.</article-title>
<source/><italic toggle="yes">Transl Psychiatry.</italic>
<year>2011</year>;<volume>1</volume>:<fpage>e55</fpage>.
<pub-id pub-id-type="doi">10.1038/tp.2011.52</pub-id>
<!--<pub-id pub-id-type="pmcid">3309470</pub-id>-->
<pub-id pub-id-type="pmid">22833210</pub-id></mixed-citation>
</ref>
<ref id="ref-112">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grozeva</surname><given-names>D</given-names></name><name><surname>Carss</surname><given-names>K</given-names></name><name><surname>Spasic-Boskovic</surname><given-names>O</given-names></name><etal></etal></person-group>:
<article-title>Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability.</article-title>
<source/><italic toggle="yes">Hum Mutat.</italic>
<year>2015</year>;<volume>36</volume>(<issue>12</issue>):<fpage>1197</fpage>–<lpage>204</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22901</pub-id>
<!--<pub-id pub-id-type="pmcid">4833192</pub-id>-->
<pub-id pub-id-type="pmid">26350204</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725777352">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-113">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serraz</surname><given-names>B</given-names></name><name><surname>Grand</surname><given-names>T</given-names></name><name><surname>Paoletti</surname><given-names>P</given-names></name></person-group>:
<article-title>Altered zinc sensitivity of NMDA receptors harboring clinically-relevant mutations.</article-title>
<source/><italic toggle="yes">Neuropharmacology.</italic>
<year>2016</year>;<volume>109</volume>:<fpage>196</fpage>–<lpage>204</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.06.008</pub-id>
<pub-id pub-id-type="pmid">27288002</pub-id></mixed-citation>
</ref>
<ref id="ref-114">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Retterer</surname><given-names>K</given-names></name><name><surname>Juusola</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>MT</given-names></name><etal></etal></person-group>:
<article-title>Clinical application of whole-exome sequencing across clinical indications.</article-title>
<source/><italic toggle="yes">Genet Med.</italic>
<year>2016</year>;<volume>18</volume>(<issue>7</issue>):<fpage>696</fpage>–<lpage>704</lpage>.
<pub-id pub-id-type="doi">10.1038/gim.2015.148</pub-id>
<pub-id pub-id-type="pmid">26633542</pub-id></mixed-citation>
</ref>
<ref id="ref-115">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>HY</given-names></name><name><surname>Alipanahi</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>LJ</given-names></name><etal></etal></person-group>:
<article-title>RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease.</article-title>
<source/><italic toggle="yes">Science.</italic>
<year>2015</year>;<volume>347</volume>(<issue>6218</issue>):<fpage>1254806</fpage>.
<pub-id pub-id-type="doi">10.1126/science.1254806</pub-id>
<!--<pub-id pub-id-type="pmcid">4362528</pub-id>-->
<pub-id pub-id-type="pmid">25525159</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725283746">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-116">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Addis</surname><given-names>L</given-names></name><name><surname>Virdee</surname><given-names>JK</given-names></name><name><surname>Vidler</surname><given-names>LR</given-names></name><etal></etal></person-group>:
<article-title>Epilepsy-associated
<italic>GRIN2A</italic> mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue.</article-title>
<source/><italic toggle="yes">Sci Rep.</italic>
<year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>66</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-017-00115-w</pub-id>
<!--<pub-id pub-id-type="pmcid">5427847</pub-id>-->
<pub-id pub-id-type="pmid">28242877</pub-id></mixed-citation>
</ref>
<ref id="ref-117">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeVries</surname><given-names>SP</given-names></name><name><surname>Patel</surname><given-names>AD</given-names></name></person-group>:
<article-title>Two patients with a
<italic>GRIN2A</italic> mutation and childhood-onset epilepsy.</article-title>
<source/><italic toggle="yes">Pediatr Neurol.</italic>
<year>2013</year>;<volume>49</volume>(<issue>6</issue>):<fpage>482</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.08.023</pub-id>
<pub-id pub-id-type="pmid">24125812</pub-id></mixed-citation>
</ref>
<ref id="ref-118">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Conroy</surname><given-names>J</given-names></name><name><surname>McGettigan</surname><given-names>PA</given-names></name><name><surname>McCreary</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Towards the identification of a genetic basis for Landau-Kleffner syndrome.</article-title>
<source/><italic toggle="yes">Epilepsia.</italic>
<year>2014</year>;<volume>55</volume>(<issue>6</issue>):<fpage>858</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1111/epi.12645</pub-id>
<pub-id pub-id-type="pmid">24828792</pub-id></mixed-citation>
</ref>
<ref id="ref-119">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Møller</surname><given-names>RS</given-names></name><name><surname>Larsen</surname><given-names>LH</given-names></name><name><surname>Johannesen</surname><given-names>KM</given-names></name><etal></etal></person-group>:
<article-title>Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies.</article-title>
<source/><italic toggle="yes">Mol Syndromol.</italic>
<year>2016</year>;<volume>7</volume>(<issue>4</issue>):<fpage>210</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1159/000448369</pub-id>
<!--<pub-id pub-id-type="pmcid">5073625</pub-id>-->
<pub-id pub-id-type="pmid">27781031</pub-id></mixed-citation>
</ref>
<ref id="ref-120">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farwell</surname><given-names>KD</given-names></name><name><surname>Shahmirzadi</surname><given-names>L</given-names></name><name><surname>El-Khechen</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions.</article-title>
<source/><italic toggle="yes">Genet Med.</italic>
<year>2015</year>;<volume>17</volume>(<issue>7</issue>):<fpage>578</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1038/gim.2014.154</pub-id>
<pub-id pub-id-type="pmid">25356970</pub-id></mixed-citation>
</ref>
<ref id="ref-121">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>NM</given-names></name><name><surname>Conroy</surname><given-names>J</given-names></name><name><surname>Shahwan</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Unexplained early onset epileptic encephalopathy: Exome screening and phenotype expansion.</article-title>
<source/><italic toggle="yes">Epilepsia.</italic>
<year>2016</year>;<volume>57</volume>(<issue>1</issue>):<fpage>e12</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1111/epi.13250</pub-id>
<pub-id pub-id-type="pmid">26648591</pub-id></mixed-citation>
</ref>
<ref id="ref-122">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Petrovski</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios.</article-title>
<source/><italic toggle="yes">Genet Med.</italic>
<year>2015</year>;<volume>17</volume>(<issue>10</issue>):<fpage>774</fpage>–<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1038/gim.2014.191</pub-id>
<!--<pub-id pub-id-type="pmcid">4791490</pub-id>-->
<pub-id pub-id-type="pmid">25590979</pub-id></mixed-citation>
</ref>
<ref id="ref-123">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>XS</given-names></name><name><surname>Reader</surname><given-names>RH</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Next-generation DNA sequencing identifies novel gene variants and pathways involved in specific language impairment.</article-title>
<source/><italic toggle="yes">Sci Rep.</italic>
<year>2017</year>;<volume>7</volume>:<fpage>46105</fpage>.
<pub-id pub-id-type="doi">10.1038/srep46105</pub-id>
<!--<pub-id pub-id-type="pmcid">5404330</pub-id>-->
<pub-id pub-id-type="pmid">28440294</pub-id></mixed-citation>
</ref>
<ref id="ref-124">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Tankovic</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>A
<italic>de novo</italic> loss-of-function
<italic>GRIN2A</italic> mutation associated with childhood focal epilepsy and acquired epileptic aphasia.</article-title>
<source/><italic toggle="yes">PLoS One.</italic>
<year>2017</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e0170818</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0170818</pub-id>
<!--<pub-id pub-id-type="pmcid">5300259</pub-id>-->
<pub-id pub-id-type="pmid">28182669</pub-id></mixed-citation>
</ref>
<ref id="ref-125">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dyment</surname><given-names>DA</given-names></name><name><surname>Tétreault</surname><given-names>M</given-names></name><name><surname>Beaulieu</surname><given-names>CL</given-names></name><etal></etal></person-group>:
<article-title>Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study.</article-title>
<source/><italic toggle="yes">Clin Genet.</italic>
<year>2015</year>;<volume>88</volume>(<issue>1</issue>):<fpage>34</fpage>–<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1111/cge.12464</pub-id>
<pub-id pub-id-type="pmid">25046240</pub-id></mixed-citation>
</ref>
<ref id="ref-126">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gahl</surname><given-names>WA</given-names></name><name><surname>Mulvihill</surname><given-names>JJ</given-names></name><name><surname>Toro</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine.</article-title>
<source/><italic toggle="yes">Mol Genet Metab.</italic>
<year>2016</year>;<volume>117</volume>(<issue>4</issue>):<fpage>393</fpage>–<lpage>400</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymgme.2016.01.007</pub-id>
<!--<pub-id pub-id-type="pmcid">5560125</pub-id>-->
<pub-id pub-id-type="pmid">26846157</pub-id></mixed-citation>
</ref>
<ref id="ref-127">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venkateswaran</surname><given-names>S</given-names></name><name><surname>Myers</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><etal></etal></person-group>:
<article-title>Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel,
<italic>de novo GRIN2A</italic> mutation.</article-title>
<source/><italic toggle="yes">Epilepsia.</italic>
<year>2014</year>;<volume>55</volume>(<issue>7</issue>):<fpage>e75</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1111/epi.12663</pub-id>
<pub-id pub-id-type="pmid">24903190</pub-id></mixed-citation>
</ref>
<ref id="ref-128">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lelieveld</surname><given-names>SH</given-names></name><name><surname>Reijnders</surname><given-names>MR</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability.</article-title>
<source/><italic toggle="yes">Nat Neurosci.</italic>
<year>2016</year>;<volume>19</volume>(<issue>9</issue>):<fpage>1194</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/nn.4352</pub-id>
<pub-id pub-id-type="pmid">27479843</pub-id></mixed-citation>
</ref>
<ref id="ref-129">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>KM</given-names></name><name><surname>da Silva</surname><given-names>C</given-names></name><name><surname>Alexander</surname><given-names>JJ</given-names></name><etal></etal></person-group>:
<article-title>Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene Panel.</article-title>
<source/><italic toggle="yes">Pediatr Neurol.</italic>
<year>2017</year>;<volume>77</volume>:<fpage>61</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.09.003</pub-id>
<pub-id pub-id-type="pmid">29056246</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732027151">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-130">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Helbig</surname><given-names>KL</given-names></name><name><surname>Farwell Hagman</surname><given-names>KD</given-names></name><name><surname>Shinde</surname><given-names>DN</given-names></name><etal></etal></person-group>:
<article-title>Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy.</article-title>
<source/><italic toggle="yes">Genet Med.</italic>
<year>2016</year>;<volume>18</volume>(<issue>9</issue>):<fpage>898</fpage>–<lpage>905</lpage>.
<pub-id pub-id-type="doi">10.1038/gim.2015.186</pub-id>
<pub-id pub-id-type="pmid">26795593</pub-id></mixed-citation>
</ref>
<ref id="ref-131">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bramswig</surname><given-names>NC</given-names></name><name><surname>Lüdecke</surname><given-names>HJ</given-names></name><name><surname>Alanay</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Exome sequencing unravels unexpected differential diagnoses in individuals with the tentative diagnosis of Coffin-Siris and Nicolaides-Baraitser syndromes.</article-title>
<source/><italic toggle="yes">Hum Genet.</italic>
<year>2015</year>;<volume>134</volume>(<issue>6</issue>):<fpage>553</fpage>–<lpage>68</lpage>.
<pub-id pub-id-type="doi">10.1007/s00439-015-1535-8</pub-id>
<pub-id pub-id-type="pmid">25724810</pub-id></mixed-citation>
</ref>
<ref id="ref-132">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dimassi</surname><given-names>S</given-names></name><name><surname>Labalme</surname><given-names>A</given-names></name><name><surname>Lesca</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>A subset of genomic alterations detected in rolandic epilepsies contains candidate or known epilepsy genes including
<italic>GRIN2A</italic> and
<italic>PRRT2</italic>.</article-title>
<source/><italic toggle="yes">Epilepsia.</italic>
<year>2014</year>;<volume>55</volume>(<issue>2</issue>):<fpage>370</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1111/epi.12502</pub-id>
<pub-id pub-id-type="pmid">24372385</pub-id></mixed-citation>
</ref>
<ref id="ref-133">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dimassi</surname><given-names>S</given-names></name><name><surname>Simonet</surname><given-names>T</given-names></name><name><surname>Labalme</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Comparison of two next-generation sequencing kits for diagnosis of epileptic disorders with a user-friendly tool for displaying gene coverage, DeCovA.</article-title>
<source/><italic toggle="yes">Appl Transl Genom.</italic>
<year>2015</year>;<volume>7</volume>:<fpage>19</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1016/j.atg.2015.10.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4803767</pub-id>-->
<pub-id pub-id-type="pmid">27054081</pub-id></mixed-citation>
</ref>
<ref id="ref-134">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>EK</given-names></name><name><surname>Rees</surname><given-names>E</given-names></name><name><surname>Walters</surname><given-names>JT</given-names></name><etal></etal></person-group>:
<article-title>Copy number variation in bipolar disorder.</article-title>
<source/><italic toggle="yes">Mol Psychiatry.</italic>
<year>2016</year>;<volume>21</volume>(<issue>1</issue>):<fpage>89</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1038/mp.2014.174</pub-id>
<!--<pub-id pub-id-type="pmcid">5038134</pub-id>-->
<pub-id pub-id-type="pmid">25560756</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725298659">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-135">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Vives</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><etal></etal></person-group>:
<article-title>Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.</article-title>
<source/><italic toggle="yes">Science.</italic>
<year>2012</year>;<volume>338</volume>(<issue>6114</issue>):<fpage>1619</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1126/science.1227764</pub-id>
<!--<pub-id pub-id-type="pmcid">3528801</pub-id>-->
<pub-id pub-id-type="pmid">23160955</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718020316">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-136">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freunscht</surname><given-names>I</given-names></name><name><surname>Popp</surname><given-names>B</given-names></name><name><surname>Blank</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Behavioral phenotype in five individuals with
<italic>de novo</italic> mutations within the
<italic>GRIN2B</italic> gene.</article-title>
<source/><italic toggle="yes">Behav Brain Funct.</italic>
<year>2013</year>;<volume>9</volume>:<fpage>20</fpage>.
<pub-id pub-id-type="doi">10.1186/1744-9081-9-20</pub-id>
<!--<pub-id pub-id-type="pmcid">3685602</pub-id>-->
<pub-id pub-id-type="pmid">23718928</pub-id></mixed-citation>
</ref>
<ref id="ref-137">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Myers</surname><given-names>RA</given-names></name><name><surname>Casals</surname><given-names>F</given-names></name><name><surname>Gauthier</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>A population genetic approach to mapping neurological disorder genes using deep resequencing.</article-title>
<source/><italic toggle="yes">PLoS Genet.</italic>
<year>2011</year>;<volume>7</volume>(<issue>2</issue>):<fpage>e1001318</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1001318</pub-id>
<!--<pub-id pub-id-type="pmcid">3044677</pub-id>-->
<pub-id pub-id-type="pmid">21383861</pub-id></mixed-citation>
</ref>
<ref id="ref-138">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hildebrand</surname><given-names>MS</given-names></name><name><surname>Myers</surname><given-names>CT</given-names></name><name><surname>Carvill</surname><given-names>GL</given-names></name><etal></etal></person-group>:
<article-title>A targeted resequencing gene panel for focal epilepsy.</article-title>
<source/><italic toggle="yes">Neurology.</italic>
<year>2016</year>;<volume>86</volume>(<issue>17</issue>):<fpage>1605</fpage>–<lpage>12</lpage>.
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002608</pub-id>
<!--<pub-id pub-id-type="pmcid">4844234</pub-id>-->
<pub-id pub-id-type="pmid">27029629</pub-id></mixed-citation>
</ref>
<ref id="ref-139">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Epi4K Consortium; Epilepsy Phenome/Genome Project</collab>,
<name><surname>Allen</surname><given-names>AS</given-names></name><name><surname>Berkovic</surname><given-names>SF</given-names></name><etal></etal></person-group>:
<article-title>
<italic>De novo</italic> mutations in epileptic encephalopathies.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>2013</year>;<volume>501</volume>(<issue>7466</issue>):<fpage>217</fpage>–<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1038/nature12439</pub-id>
<!--<pub-id pub-id-type="pmcid">3773011</pub-id>-->
<pub-id pub-id-type="pmid">23934111</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718071356">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-140">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Stessman</surname><given-names>HA</given-names></name><name><surname>Boyle</surname><given-names>EA</given-names></name><etal></etal></person-group>:
<article-title>Recurrent
<italic>de novo</italic> mutations implicate novel genes underlying simplex autism risk.</article-title>
<source/><italic toggle="yes">Nat Commun.</italic>
<year>2014</year>;<volume>5</volume>: 5595.
<pub-id pub-id-type="doi">10.1038/ncomms6595</pub-id>
<!--<pub-id pub-id-type="pmcid">4249945</pub-id>-->
<pub-id pub-id-type="pmid">25418537</pub-id></mixed-citation>
</ref>
<ref id="ref-141">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fokstuen</surname><given-names>S</given-names></name><name><surname>Makrythanasis</surname><given-names>P</given-names></name><name><surname>Hammar</surname><given-names>E</given-names></name><etal></etal></person-group>:
<article-title>Experience of a multidisciplinary task force with exome sequencing for Mendelian disorders.</article-title>
<source/><italic toggle="yes">Hum Genomics.</italic>
<year>2016</year>;<volume>10</volume>(<issue>1</issue>): 24.
<pub-id pub-id-type="doi">10.1186/s40246-016-0080-4</pub-id>
<!--<pub-id pub-id-type="pmcid">4924303</pub-id>-->
<pub-id pub-id-type="pmid">27353043</pub-id></mixed-citation>
</ref>
<ref id="ref-142">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lucariello</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>E</given-names></name><name><surname>Vidal</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype.</article-title>
<source/><italic toggle="yes">Hum Genet.</italic>
<year>2016</year>;<volume>135</volume>(<issue>12</issue>):<fpage>1343</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1007/s00439-016-1721-3</pub-id>
<!--<pub-id pub-id-type="pmcid">5065581</pub-id>-->
<pub-id pub-id-type="pmid">27541642</pub-id></mixed-citation>
</ref>
<ref id="ref-143">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yavarna</surname><given-names>T</given-names></name><name><surname>Al-Dewik</surname><given-names>N</given-names></name><name><surname>Al-Mureikhi</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>High diagnostic yield of clinical exome sequencing in Middle Eastern patients with Mendelian disorders.</article-title>
<source/><italic toggle="yes">Hum Genet.</italic>
<year>2015</year>;<volume>134</volume>(<issue>9</issue>):<fpage>967</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1007/s00439-015-1575-0</pub-id>
<pub-id pub-id-type="pmid">26077850</pub-id></mixed-citation>
</ref>
<ref id="ref-144">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Firth</surname><given-names>HV</given-names></name><name><surname>Richards</surname><given-names>SM</given-names></name><name><surname>Bevan</surname><given-names>AP</given-names></name><etal></etal></person-group>:
<article-title>DECIPHER:
<italic>D</italic>atabas
<italic>e</italic> of
<italic>C</italic>hromosomal
<italic>I</italic>mbalance and
<italic>P</italic>henotype in
<italic>H</italic>umans Using
<italic>E</italic>nsembl
<italic>R</italic>esources.</article-title>
<source/><italic toggle="yes">Am J Hum Genet.</italic>
<year>2009</year>;<volume>84</volume>(<issue>4</issue>):<fpage>524</fpage>–<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ajhg.2009.03.010</pub-id>
<!--<pub-id pub-id-type="pmcid">2667985</pub-id>-->
<pub-id pub-id-type="pmid">19344873</pub-id></mixed-citation>
</ref>
<ref id="ref-145">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smigiel</surname><given-names>R</given-names></name><name><surname>Kostrzewa</surname><given-names>G</given-names></name><name><surname>Kosinska</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Further evidence for
<italic>GRIN2B</italic> mutation as the cause of severe epileptic encephalopathy.</article-title>
<source/><italic toggle="yes">Am J Med Genet A.</italic>
<year>2016</year>;<volume>170</volume>(<issue>12</issue>):<fpage>3265</fpage>–<lpage>70</lpage>.
<pub-id pub-id-type="doi">10.1002/ajmg.a.37887</pub-id>
<pub-id pub-id-type="pmid">27605359</pub-id></mixed-citation>
</ref>
<ref id="ref-146">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bosch</surname><given-names>DG</given-names></name><name><surname>Boonstra</surname><given-names>FN</given-names></name><name><surname>de Leeuw</surname><given-names>N</given-names></name><etal></etal></person-group>:
<article-title>Novel genetic causes for cerebral visual impairment.</article-title>
<source/><italic toggle="yes">Eur J Hum Genet.</italic>
<year>2016</year>;<volume>24</volume>(<issue>5</issue>):<fpage>660</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1038/ejhg.2015.186</pub-id>
<!--<pub-id pub-id-type="pmcid">4930090</pub-id>-->
<pub-id pub-id-type="pmid">26350515</pub-id></mixed-citation>
</ref>
<ref id="ref-147">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Srour</surname><given-names>M</given-names></name><name><surname>Capo-Chichi</surname><given-names>JM</given-names></name><etal></etal></person-group>:
<article-title>
<italic>De Novo</italic> Mutations in Moderate or Severe Intellectual Disability.</article-title>
<source/><italic toggle="yes">PLoS Genet.</italic>
<year>2014</year>;<volume>10</volume>(<issue>10</issue>):<fpage>e1004772</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1004772</pub-id>
<!--<pub-id pub-id-type="pmcid">4214635</pub-id>-->
<pub-id pub-id-type="pmid">25356899</pub-id></mixed-citation>
</ref>
<ref id="ref-148">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takasaki</surname><given-names>Y</given-names></name><name><surname>Koide</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Mutation screening of
<italic>GRIN2B</italic> in schizophrenia and autism spectrum disorder in a Japanese population.</article-title>
<source/><italic toggle="yes">Sci Rep.</italic>
<year>2016</year>;<volume>6</volume>: 33311.
<pub-id pub-id-type="doi">10.1038/srep33311</pub-id>
<!--<pub-id pub-id-type="pmcid">5018849</pub-id>-->
<pub-id pub-id-type="pmid">27616045</pub-id></mixed-citation>
</ref>
<ref id="ref-149">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morisada</surname><given-names>N</given-names></name><name><surname>Ioroi</surname><given-names>T</given-names></name><name><surname>Taniguchi-Ikeda</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>A 12p13
<italic>GRIN2B</italic> deletion is associated with developmental delay and macrocephaly.</article-title>
<source/><italic toggle="yes">Hum Genome Var.</italic>
<year>2016</year>;<volume>3</volume>: 16029.
<pub-id pub-id-type="doi">10.1038/hgv.2016.29</pub-id>
<!--<pub-id pub-id-type="pmcid">5023786</pub-id>-->
<pub-id pub-id-type="pmid">27656287</pub-id></mixed-citation>
</ref>
<ref id="ref-150">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dimassi</surname><given-names>S</given-names></name><name><surname>Andrieux</surname><given-names>J</given-names></name><name><surname>Labalme</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Interstitial 12p13.1 deletion involving
<italic>GRIN2B</italic> in three patients with intellectual disability.</article-title>
<source/><italic toggle="yes">Am J Med Genet A.</italic>
<year>2013</year>;<volume>161A</volume>(<issue>10</issue>):<fpage>2564</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1002/ajmg.a.36079</pub-id>
<pub-id pub-id-type="pmid">23918416</pub-id></mixed-citation>
</ref>
<ref id="ref-151">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Kouzmitcheva</surname><given-names>E</given-names></name><name><surname>Orsino</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Chromosome 12p Deletion Spanning the GRIN2B Gene Presenting With a Neurodevelopmental Phenotype: A Case Report and Review of Literature.</article-title>
<source/><italic toggle="yes">Child Neurol Open.</italic>
<year>2016</year>;<volume>3</volume>: 2329048X16629980.
<pub-id pub-id-type="doi">10.1177/2329048X16629980</pub-id>
<!--<pub-id pub-id-type="pmcid">5417284</pub-id>-->
<pub-id pub-id-type="pmid">28503605</pub-id></mixed-citation>
</ref>
<ref id="ref-152">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Blumenthal</surname><given-names>I</given-names></name><etal></etal></person-group>:
<article-title>Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries.</article-title>
<source/><italic toggle="yes">Cell.</italic>
<year>2012</year>;<volume>149</volume>(<issue>3</issue>):<fpage>525</fpage>–<lpage>37</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2012.03.028</pub-id>
<!--<pub-id pub-id-type="pmcid">3340505</pub-id>-->
<pub-id pub-id-type="pmid">22521361</pub-id></mixed-citation>
</ref>
<ref id="ref-153">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griswold</surname><given-names>AJ</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Cukier</surname><given-names>HN</given-names></name><etal></etal></person-group>:
<article-title>Evaluation of copy number variations reveals novel candidate genes in autism spectrum disorder-associated pathways.</article-title>
<source/><italic toggle="yes">Hum Mol Genet.</italic>
<year>2012</year>;<volume>21</volume>(<issue>15</issue>):<fpage>3513</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/dds164</pub-id>
<!--<pub-id pub-id-type="pmcid">3392110</pub-id>-->
<pub-id pub-id-type="pmid">22543975</pub-id></mixed-citation>
</ref>
<ref id="ref-154">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lal</surname><given-names>D</given-names></name><name><surname>Steinbrücker</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Investigation of
<italic>GRIN2A</italic> in common epilepsy phenotypes.</article-title>
<source/><italic toggle="yes">Epilepsy Res.</italic>
<year>2015</year>;<volume>115</volume>:<fpage>95</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2015.05.010</pub-id>
<pub-id pub-id-type="pmid">26220384</pub-id></mixed-citation>
</ref>
<ref id="ref-155">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Lau</surname><given-names>M</given-names></name><name><surname>Ayers</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>
<italic>De Novo</italic> Heterogeneous Mutations in SCN2A and GRIN2A Genes and Seizures With Ictal Vocalizations.</article-title>
<source/><italic toggle="yes">Clin Pediatr (Phila).</italic>
<year>2016</year>;<volume>55</volume>(<issue>9</issue>):<fpage>867</fpage>–<lpage>70</lpage>.
<pub-id pub-id-type="doi">10.1177/0009922815601060</pub-id>
<pub-id pub-id-type="pmid">26283219</pub-id></mixed-citation>
</ref>
<ref id="ref-156">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wollmuth</surname><given-names>LP</given-names></name><name><surname>Kuner</surname><given-names>T</given-names></name><name><surname>Sakmann</surname><given-names>B</given-names></name></person-group>:
<article-title>Adjacent asparagines in the NR2-subunit of the NMDA receptor channel control the voltage-dependent block by extracellular Mg
<sup>2+</sup>.</article-title>
<source/><italic toggle="yes">J Physiol.</italic>
<year>1998</year>;<volume>506</volume>(<issue>Pt 1</issue>):<fpage>13</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1469-7793.1998.013bx.x</pub-id>
<!--<pub-id pub-id-type="pmcid">2230696</pub-id>-->
<pub-id pub-id-type="pmid">9481670</pub-id></mixed-citation>
</ref>
<ref id="ref-157">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mayer</surname><given-names>ML</given-names></name></person-group>:
<article-title>Glutamate receptors at atomic resolution.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>2006</year>;<volume>440</volume>(<issue>7083</issue>):<fpage>456</fpage>–<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1038/nature04709</pub-id>
<pub-id pub-id-type="pmid">16554805</pub-id></mixed-citation>
</ref>
<ref id="ref-158">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Platzer</surname><given-names>K</given-names></name><name><surname>Lemke</surname><given-names>JR</given-names></name></person-group>:
<article-title>
<italic>GRIN2B</italic>-Related Neurodevelopmental Disorder.</article-title>In: Adam MP, Ardinger HH, Pagon RA,
<italic>et al.</italic>: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2019.<year>2018</year>; May 31.
<pub-id pub-id-type="pmid">29851452</pub-id></mixed-citation>
</ref>
<ref id="ref-159">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreoli</surname><given-names>V</given-names></name><name><surname>de Marco</surname><given-names>EV</given-names></name><name><surname>Trecroci</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Potential involvement of GRIN2B encoding the NMDA receptor subunit NR2B in the spectrum of Alzheimer's disease.</article-title>
<source/><italic toggle="yes">J Neural Transm (Vienna).</italic>
<year>2014</year>;<volume>121</volume>(<issue>5</issue>):<fpage>533</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1007/s00702-013-1125-7</pub-id>
<pub-id pub-id-type="pmid">24292895</pub-id></mixed-citation>
</ref>
<ref id="ref-160">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Roak</surname><given-names>BJ</given-names></name><name><surname>Vives</surname><given-names>L</given-names></name><name><surname>Girirajan</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Sporadic autism exomes reveal a highly interconnected protein network of
<italic>de novo</italic> mutations.</article-title>
<source/><italic toggle="yes">Nature.</italic>
<year>2012</year>;<volume>485</volume>(<issue>7397</issue>):<fpage>246</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="doi">10.1038/nature10989</pub-id>
<!--<pub-id pub-id-type="pmcid">3350576</pub-id>-->
<pub-id pub-id-type="pmid">22495309</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/716397823">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-161">
<label>161</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soto</surname><given-names>D</given-names></name><name><surname>Altafaj</surname><given-names>X</given-names></name><name><surname>Sindreu</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Glutamate receptor mutations in psychiatric and neurodevelopmental disorders.</article-title>
<source/><italic toggle="yes">Commun Integr Biol.</italic>
<year>2014</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e27887</fpage>.
<pub-id pub-id-type="doi">10.4161/cib.27887</pub-id>
<!--<pub-id pub-id-type="pmcid">3937208</pub-id>-->
<pub-id pub-id-type="pmid">24605182</pub-id></mixed-citation>
</ref>
<ref id="ref-162">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delahanty</surname><given-names>RJ</given-names></name><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Brune</surname><given-names>CW</given-names></name><etal></etal></person-group>:
<article-title>Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism.</article-title>
<source/><italic toggle="yes">Mol Psychiatry.</italic>
<year>2011</year>;<volume>16</volume>(<issue>1</issue>):<fpage>86</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1038/mp.2009.118</pub-id>
<!--<pub-id pub-id-type="pmcid">3428055</pub-id>-->
<pub-id pub-id-type="pmid">19935738</pub-id></mixed-citation>
</ref>
<ref id="ref-163">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>YW</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Cai</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Synaptic clustering differences due to different
<italic>GABRB3</italic> mutations cause variable epilepsy syndromes.</article-title>
<source/><italic toggle="yes">Brain.</italic>
<year>2019</year>;<volume>142</volume>(<issue>10</issue>):<fpage>3028</fpage>–<lpage>3044</lpage>.
<pub-id pub-id-type="doi">10.1093/brain/awz250</pub-id>
<!--<pub-id pub-id-type="pmcid">6776116</pub-id>-->
<pub-id pub-id-type="pmid">31435640</pub-id></mixed-citation>
</ref>
<ref id="ref-164">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janve</surname><given-names>VS</given-names></name><name><surname>Hernandez</surname><given-names>CC</given-names></name><name><surname>Verdier</surname><given-names>KM</given-names></name><etal></etal></person-group>:
<article-title>Epileptic encephalopathy
<italic>de novo</italic> GABRB mutations impair γ-aminobutyric acid type A receptor function</article-title>
<source/><italic toggle="yes">Ann Neurol.</italic>
<year>2016</year>;<volume>79</volume>(<issue>5</issue>):<fpage>806</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1002/ana.24631</pub-id>
<!--<pub-id pub-id-type="pmcid">5014730</pub-id>-->
<pub-id pub-id-type="pmid">26950270</pub-id></mixed-citation>
</ref>
<ref id="ref-165">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Constantine-Paton</surname><given-names>M</given-names></name></person-group>:
<article-title>Eye opening rapidly induces synaptic potentiation and refinement.</article-title>
<source/><italic toggle="yes">Neuron.</italic>
<year>2004</year>;<volume>43</volume>(<issue>2</issue>):<fpage>237</fpage>–<lpage>49</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuron.2004.06.031</pub-id>
<pub-id pub-id-type="pmid">15260959</pub-id></mixed-citation>
</ref>
<ref id="ref-166">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotermanski</surname><given-names>SE</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group>:
<article-title>Mg
<sup>2+</sup> imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.</article-title>
<source/><italic toggle="yes">J Neurosci.</italic>
<year>2009</year>;<volume>29</volume>(<issue>9</issue>):<fpage>2774</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3703-08.2009</pub-id>
<!--<pub-id pub-id-type="pmcid">2679254</pub-id>-->
<pub-id pub-id-type="pmid">19261873</pub-id></mixed-citation>
</ref>
<ref id="ref-167">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glasgow</surname><given-names>NG</given-names></name><name><surname>Wilcox</surname><given-names>MR</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group>:
<article-title>Effects of Mg
<sup>2+</sup> on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.</article-title>
<source/><italic toggle="yes">Neuropharmacology.</italic>
<year>2018</year>;<volume>137</volume>:<fpage>344</fpage>–<lpage>58</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.05.017</pub-id>
<!--<pub-id pub-id-type="pmcid">6050087</pub-id>-->
<pub-id pub-id-type="pmid">29793153</pub-id></mixed-citation>
</ref>
<ref id="ref-168">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perszyk</surname><given-names>RE</given-names></name><name><surname>DiRaddo</surname><given-names>JO</given-names></name><name><surname>Strong</surname><given-names>KL</given-names></name><etal></etal></person-group>:
<article-title>GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.</article-title>
<source/><italic toggle="yes">Mol Pharmacol.</italic>
<year>2016</year>;<volume>90</volume>(<issue>6</issue>):<fpage>689</fpage>–<lpage>702</lpage>.
<pub-id pub-id-type="doi">10.1124/mol.116.105130</pub-id>
<!--<pub-id pub-id-type="pmcid">5118640</pub-id>-->
<pub-id pub-id-type="pmid">27625038</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>